Jahresbericht Dermatologie USZ 2015/2016

Department of Dermatology

Biennial Report 2015 /2016

Imprint Project lead: Prof. Dr. med. Lars French, Catherine Frey-Blanc Contact: c.frey-blanc@usz.ch Layout: info@klauserdesign.ch Print: N&E Print, Siebnen Edition: 900 Expl.

Copyright by Department of Dermatology, University Hospital Zurich

Table of Content

Editorial 4

1 Assignment

6

2 Mission Statement

7

3 Team

8

4 Patient Care including Laboratories

10

5 Quality Management

15

6 Research

16

7

Clinical Research: The University Hospital Zurich Dermatology Clinical Trial Unit

32

8

Research Priority Programs: URPP (Universitary Research Priority Project) and Skintegrity

34

9 Collaborations with other Dermatology Centers

36

10

37

Research Collaborations – Foundations and Associations: Foundation Bruno Bloch, Association for Research on Cancer of the Skin, Foundation Promedica, Christine Kühne Center for Allergy Research and Education CK-CARE

11 Medical Education and Training

40

12 Public Relations and 100 Year Anniversary

46

13 Museum of Wax Moulages

48

14 Honoraries and Prizes

49

15 Partners, Sponsors, Collaboration with Industry and Fundraising

51

16 Publications 2015 and 2016

52

Editorial

Dear colleagues, friends, referring physicians, patients, partners and readers. It is my pleasure, together with my team at the Department of Dermatology of the University Hospital Zurich, to provide you with an update of our recent activities within this biennial report.

The time frame covered by this biennial report represents my 9th and 10th years chairing the department and continued devotion towards our driving aim of providing high quality patient care, research and education in the fields of dermatology, venerology and allergology, with a focus on research and innovation in dermatooncology, immuno-dermatology and allergology.

In the last two years, we have seen the fruits of our efforts in in-house training of talented clinicians, clinician-scientists and scientists. Several of these have become junior faculty and are now actively contributing to sustain quality of care and innovation in the department. Of note is the funding by the Promedica and Bruno-Bloch Foundations of an endowed professorship for immuno-dermatology, which has been attributed in a competitive selection process to one of our talented junior clinician-scientists, Dr A. Navarini. With this new professorship, Prof. Navarini will strive to further develop his research in the field of neutrophil-mediated skin diseases and strengthen our clinical immuno-dermatology program. Likewise, Dr M. Levesque – an outstanding scientist with an endowed professorship from the department’s Skin Cancer Foundation who has been very successful in promoting both our melanoma research and the development of an extensive Biobank with live primary tumor cell lines linked to genomic and clinical data – has received a tenure-track position at our department and university.

Our research efforts have also received a considerable boost by unique competitive funding opportunities. Firstly, our focus on cutaneous oncology is being promoted in the context of a university-wide Research of Priority Program in translational oncology financed with over 6 million Swiss Francs from 2012–2016 under my direction in collaboration with 11 outstanding physicians and scientists from the University of Zurich (www.cancer.uzh.ch). Based on a recent outstanding interim external evaluation, a further 4 years of funding with over 11 million Swiss Francs from 2017–2020 have been promised. Second, several members of the Department of Dermatology in collaboration with clinician-scientists in rheumatology, plastic surgery, angiology and pediatrics, as well as scientists and engineers from the University of Zurich and the Swiss Federal Institute of Technology in Zurich (ETHZ) under the direction of Prof. S. Werner (ETHZ) and Prof. L. French won competitive seed-funding of 1 million Swiss Francs for a project called Skintegrity (www.hochschulmedizin.ch). The Skintegrity consortium in Zurich brings together leading experts in the above areas to address the need for more efficient diagnosis and therapy of major skin diseases and of acute and chronic wounds.

At a clinical level, the significant innovations in the therapy of skin cancer and inflammatory disorders enabled us in the last two years to provide our over 22,000 outpatients (70,000 patient-visits per year) and 1100 inpatients per year a higher standard of care than previously. During this period, thirteen of our residents in training became successfully board-certified in dermatology and venerology (Drs N. Galliker, N.H. Gräni, Y. Göksu, D. Jenni, M. Glatz, P. KränzlinStieger, M. Kunz, C. Luder, J. Mangana, S. Micaletto, C. Murer, Ch. Steinmann, L. Wiederkehr), whereas five achieved board-certification in allergology/immunology (Drs J. Genser, M. Glatz, C. Lang, S. Micaletto, K. Schiesser), two in general internal medicine (Drs S. Conrad, K. Kaufmann-Schad) and one in pathology (Dr M. Drach). In 2015–2016 three of our senior physicians (Drs E. Guenova, S. Läuchli and L. Weibel) and one of our senior-scientists (Dr H.-D. Beer) were recognized by our university for their academic achievements and awarded the Venia Legendi. Last but not least, in 2016 our deputy chair Prof. R. Dummer, was promoted to the status of extraordinary professor at the University of Zurich in recognition for his outstanding clinical and academic achievements. Our warmest congratulations go to all the persons mentioned above.

4

With over 40 interventional clinical trials running currently in skin cancer and inflammatory skin diseases, and in the context of an ongoing professionalization of our clinical trial unit, we are very fortunate that one of our board-certified physicians, PD Dr S. Goldinger, recently successfully completed a second board certification in Pharmaceutical Medicine. She is now responsible for our certified clinical trials unit including a Swiss Association for Clinical Cancer Research (SAKK)-certified phase I clinical trials unit.

2015 was also a special year for the departments Bruno Bloch Foundation that strives to raise money for supporting research and education in the department. On the 3rd of November 2015, the foundation organized successfully a gala concert for fundraising with the Zurich Chamber Orchestra and renowned soprano Edita Gruberova for over 1000 attendees at the Zurich Tonhalle. Our department and the Bruno Bloch Foundation are extremely grateful to the above artists, the generous participants and donators for their generous support.

Challenges are to come and we are preparing ourselves for these. The biggest challenge alongside the continuously rising financial pressure will be the relocation as of 2020 of our outpatient clinics to the ambulatory university medical center, the University Hospital Zurich Airport (UHZ Airport, see www.usz.ch/bau) being built at Zurich Airport. Detailed plans for the Department of Dermatology in the top floor of this university medical center are finalized so that as of 2020 our department will have clinical operations at the existing central campus of the university hospital and UHZ Airport.

This certainly is a challenge from a management and team perspective, but also an opportunity, given the modern facilities and additional space available for us at UHZ Airport.

With this overview of selected milestones and developments for the period 2015–2016, I invite you in the name of my entire team to discover more in the following pages. Enjoy!

Prof. Lars E. French, MD Chairman Department of Dermatology University Hospital Zurich

5

1 Assignment of the Department of Dermatology University Hospital Zurich

The Department of Dermatology at University Hospital Zurich (UHZ) is devoted to the provision of sustained leadership in research, patient care and education in the fields of dermatology, venereology and allergology.

Our nationally and internationally recognized department includes centers of excellence for skin cancer, inflammatory and allergic skin diseases, and dermatological surgery. With a team of 47 specialist physicians, we offer high-level patient care in all areas of dermatology, venereology and allergology in the context of our large outpatient care clinic (Dermatologische Poliklinik), our inpatient dermatology service, our daycare unit and the tertiary care referral clinics for a large number of specialty areas, including melanoma and difficult pigmented lesions, non-melanoma skin cancers, cutaneous lymphoma, bullous and autoimmune skin disease, medical dermatology, psoriasis, hair and scalp disease, occupational and contact dermatitis, dermatologic surgery, dermatopathology and physical therapies (phototherapy, radiotherapy and laser therapy).

6

Our research activities focus on basic and translational research with relevance to skin disease, primarily skin cancer and inflammatory skin disease. The efforts of our research groups are reflected by regular high-level publications and a high cumulative yearly impact factor.

Collaboration and networking with talented scientists and research groups at the University of Zurich, ETH, collaborative networks such as the Cancer Network Zurich, and other leading European dermatology centers considerably strengthens our research activities. Education is the third principle field of activity for our department. In the past few years, the department has focused its resources on pre and post-graduate training and on the development and maintenance of our innovative internet-based pre-graduate learning tool – DOIT (Dermatology Online with Interactive Technology) – in collaboration with the European Dermatology Forum.

2 Mission Statement

The top priorities of the Department of Dermatology – in close collaboration with other departments and institutes at UHZ – are to:

offer high quality individual diagnosis and therapy of skin disease, and patient education in skincare and prevention of skin disease

provide a high level of teaching and training in dermatology at the pre and post-graduate level

perform innovative basic and clinical research with the ultimate aim of contributing to improved patient care

foster constructive collaboration and networks with private practitioners and primary and secondary institutional care providers

Through fulfillment of this mission, we aim to position our department among the leading dermatology departments in Europe.

7

3 Team

Team of Physicians of Department of Dermatology

Team of Personal Assistants to our Executive Physicians

Team of Administration

Page 9: – Attending Physicians with extended responsibility: equivalent of Assistant Professor level – Senior Attending Physicians: equivalent of Associate Professor level 8

Department of Dermatology Chair

Vice-Chair

Prof. Lars French, MD

Prof. Reinhard Dummer, MD

Senior Attending Physicians

Head Nursing

Skin Cancer Prevention, Quality Management

Inpatient Clinic, Dermatosurgery

Outpatient Clinic, Research, Laboratories

Allergology Unit, Teaching

Prof. Ralph Braun, MD

Prof. Jürg Hafner, MD

Prof. Thomas Kündig, MD

Prof. Peter SchmidGrendelmeier, MD

Clinical Manager

Sandra Beeler Trüssel

Alexander Kitzinger

Attending Physicians with extended responsibility Dermatopathology

Dermatopathology, Cutaneous Lymphoma

Dermatosurgery

Inpatient Clinic, Dermtooncology

Outpatient Clinic, Research

PD Jivko Kamarachev, MD

PD Katrin Kerl, MD

PD Severin Läuchli, MD

Prof. Mirjana Maiwald, MD

Prof. Alexander Navarni, MD, PhD

Attending Physicians Outpatient Clinic, Day Care Unit

Dermatosurgery

Museum of Wax Moulages

Allergology Unit

Allergology Unit

Dermatooncoloy, Clinical Trials

Outpatient Clinic

Dermatooncology, Cutaneous Lymphoma

Physical Treatments

Marjam Barysch, MD

Sabine Bruckert, MD

Michael Geiges, MD

Julia Genser, MD

Martin Glatz, MD

PD Simone Goldinger, MD

Nora Gräni, MD

PD Emmanuella Guenova, MD, PhD

Laurence Imhof, MD

Dermatooncology, Cutaneous Lymphoma

Dermatopathology

Dermatopathology

Outpatient Clinic

Inpatient Clinic, Immunosuppression Clinic

Dermatosurgery

Pediatric Dermatology

Pediatric Dermatology

Joanna Mangana, MD

Prof. Dmitry Kazakov, MD

Dr. med.

Beda Mühleisen

Carla Murer, MD

Mirjam Nägeli, MD

Stephan Nobbe, MD

Martin Theiler, MD

PD Lisa Weibel, MD

Fellows Inpatient Clinic

Samuel Conrad, MD

Outpatient Clinic, Allergology Unit

Nadja Galliker, MD

Outpatient Clinic

Allergology Unit

Pediatric Dermatology

Pascale Kränzlin, MD

Sara Micaletto, MD

Regula Wälchli, MD

(as per April 2017)

9

4 Patient Care including Laboratories

Prof. Th. Kündig, Head, and Prof. A. Navarini, Vice-Head Outpatient Clinic

In the Swiss health service, inpatient dermatology is available almost exclusively at the five university hospitals.

In contrast, outpatient care is offered in both the private sector and the public setting of university and cantonal hospitals. The largest academic dermatology center in Switzerland, the Department of Dermatology at UHZ, offers state-of-the-art inpatient medical care for complex and rare skin problems. The department’s skilled surgeons perform complex surgical procedures and histologically controlled procedures. In addition, our department is able to administer complex chemotherapeutic regimens and intravenous immunotherapy, including antibodies and fusion molecules. We also provide an extensive spectrum of outpatient services, including highly specialized consultations. Our department benefits from a large area referral base for these specialist activities and its own on-site histopathology laboratory.

Outpatient unit (polyclinic) and specialist care clinics Prof. Th. M. Kündig and his team of dermatologists and specialist nurses treat more than 22,000 patients on referral in more than 70,000 consultations a year. In addition to the general outpatient clinics, patients profit

10

from international experts in their fields of dermatology and verenereology in outpatient clinics for autoimmune disorders, psoriasis, atopic eczema, acne and other severe dermatologic diseases. An interdisciplinary wound clinic is provided once a week in collaboration with the departments of vascular surgery, angiology, orthopedics and plastic surgery for patients with chronic hard-to-heal wounds. In 2016, a new consultation for acne inversa was established, managed by Prof. A. Navarini and PD Dr S. Läuchli (co-management).

In our daycare unit, infusion therapies are performed in an outpatient setting. Most of our patients suffer from metastatic melanoma and are treated mainly with recently developed immunotherapies and targeted therapies – as highly effective treatment modalities. Only in minor cases is chemotherapy still used. Further treated diseases include inflammatory and autoimmune diseases, and cutaneous lymphoma. Due to the relocation to one room (C19), we have improved the monitoring capabilities, as one nurse and one physician can be on-site. The new rapid blood laboratory analysis system enables treatment of shorter duration. We are still working on further improvements in order to ensure the stay at our day clinic is as convenient as possible.

The skin cancer center of the department integrated in the Cancer Center Zurich Our skin cancer center runs under the direction of Prof.

R. Dummer with a team of expert skin cancer specialists (Prof. R. Braun, Prof. G. Hofbauer, PD Dr A. Cozzio, PD Dr E. Guenova, PD Dr S. Goldinger PD Dr K. Kerl, Prof. M. Maiwald, Dr J. Mangana and Dr S. Goldinger), and is comprised of the following clinics: The pigmented lesion & skin cancer prevention clinic: this clinic runs under the direction of Prof. R. Braun and makes use of modern high tech equipment (confocal microscopy, skin surface videomicroscopy, dermoscopy, total body imaging) for the early detection of melanoma. The skin cancer clinic runs under the direction of Prof. R. Dummer and offers patients with skin cancer of different types (melanoma and non-melanoma skin cancer) highly professionalized treatment and follow-up as well as access to the most innovative clinical trials. The cutaneous lymphoma clinic runs under the direction of PD Dr A. Cozzio and since April 2016 of PD Dr K. Kerl & PD Dr E. Guenova.

With the incidence of melanoma and other skin cancers growing worldwide and new therapies prolonging the survival of patients with advanced disease, complex medical care is needed. Best care of complicated melanoma and skin cancer cases is achieved in specialized referral centers such as the Zurich skin cancer center integrated in the cancer center of the university hospital (www.cancercenter.ch). Our aim to provide optimized melanoma therapy, best patient reported treatment outcome and successful clinical and translational research, necessitates a dedicated inter-disciplinary team.

Modern skin cancer management is a paradigm for precision medicine in a rapidly evolving scientific environment.

Networking and cooperative projects with basic research on a local, national and international level is crucial. It is especially attractive to include well established local basic research groups and cooperative projects including the investigation of patient samples collected in the biobank. Clinical research with Pharma-sponsored and investigator initiated clinical trials is necessary to create a critical understanding of clinical science. Patients are regularly informed about these projects and may even actively support these efforts.

Allergology unit The allergology unit of our department is a European certified (GALEN) center of excellence in the diagnosis and treatment of acute and chronic allergic disease.

Managed by Prof. P. Schmid and his staff, our unit has

developed a special focus on skin allergy, food allergy, drug allergy and desensitization protocols (specific immunotherapy); for example, including life-threatening insect sting allergies. Outpatient clinics for patients with atopic dermatitis, drug hypersensitivity, mastocytosis and hereditary angioedema complete the general clinics. Translational research involves mainly these diseases, with, for example, investigation by Dr M. Glatz and Dr Ph. Bosshard on the effect of the microbiome on atopic eczema.

Other approaches focus on the role of food allergens and histamine intolerance, and mast cell-associated diseases.

Special attention is also given to inter-professional patient education, based on individual and patient-tailored instructional steps (micro-education) and counseling.

Dermatosurgery Our dermatosurgery unit and its experienced team of dermatologic surgeons (PD Dr S. Läuchli and Prof. J. Hafner) have developed a renowned area in general dermatologic surgery with a focus on skin cancer surgery and chronic wound surgery. High-end techniques, such as micrographic surgery (MOHS) for complex skin cancer cases, ablative laser treatments or fibrotic tissue shaving and skin transplantation for complex wounds, are performed regularly with a high level of patient satisfaction in this unit.

Physical treatment unit – including radiotherapy, phototherapy and laser unit This unit, led by Prof. R. Dummer and Dr L. Imhof, is equipped with the latest physical therapy technologies, including UVA1 devices, a full range of lasers and an Intense Pulsed Light (IPL) platform.

Recently, two modern X-ray devices for superficial radiotherapy of skin cancer and selected refractory inflamma-

11

tory diseases have been installed. Over 3,000 treatments are performed per year.

The Department of Dermatology has a long-lasting interest in the application of laser technology. The laser therapy and aesthetic dermatology unit attracts patients from all over the world seeking treatment for aesthetic and skin conditions. We perform a full range of laser procedures, such as permanent hair removal, tattoo removal, laser treatments of vascular disorders, fractional resurfacing, fractional CO2 and fractional erbium treatments, skin-tightening procedures and traditional CO2 and erbium-resurfacing treatments. Additionally we perform numerous other treatments such as injections with botulinumtoxin, soft tissue fillers and chemical peels.

Dr L. Imhof, the director of the laser unit, collaborates in an interdisciplinary manner with plastic surgeons, angiologists and gynecologists.

Our inpatient clinic With 36 beds, 12 of which are available for semi-private and privately insured patients, this unit is unique with respect to the medical expertise and the level of integrated medical and dermatological care that the highly specialized and committed team of nurses and doctors offers. Under the direction of senior medical staff (Prof.

L. French, Prof. R. Dummer, Prof. J. Hafner, Prof. M. Maiwald, Dr M. Nägeli) solutions are found for the management of particularly severe forms of skin disease. The most common diagnoses include therapy-resistant forms of psoriasis and atopic dermatitis, medical and surgical treatment of advanced forms of skin cancer, treatment of complex autoimmune skin disease, closure of chronic wounds, and examination of any complex and/or extended forms of skin disease for which an appropriate diagnostic and therapeutic approach needs to be put in place. The concentrated medical expertise and friendly atmosphere are highly appraised by the patients.

Weekday inpatient ward Nursing care Our weekday inpatient ward under the direction of Dr M. Nägeli has 8 beds to provide rapid, complex inpatient workups and short inpatient therapies. This unit also offers extracorporeal photopheresis, an immunomodulatory treatment, to stem cell transplant recipients with graft-versus-host-disease, to lung transplant recipients suffering organ rejection, and to cutaneous lymphoma patients with three photopheresis units. In January 2017 we will extend to 4 photopheresis machines. On the same floor there is the bath therapy room to fulfill complex dermatological therapies.

12

Two recent personnel changes have bolstered the clinic: Heiko Müller has been working as a healthcare expert since September 2015, and in October 2016 Angela Andreoletti took over the management of inpatient care.

The most important goals of nursing care are based on the three-pillar concept of UHZ Shared Governance: expertise, education and management. These elements are closely interrelated and require the best possible collaboration from the team. The various skills of the staff

In this context, the position of a skin cancer nurse was created in autumn 2016, financed by the Verein für Haukrebsforschung (see page 38). The nurse accompanies the patients continuously from the initial diagnosis to the unfortunately often terminal stage of the disease. She is the constant point of contact for patients and relatives and coordinates contact with psycho-oncology and social services (contact with palliative medicine: by our physicians). We created this position in order to be able to address urgent demands from our patients, who in these often very difficult situations need a support person for questions and information on clinical studies.

must be used in a targeted manner in order to maintain quality assurance and patient safety at the highest level.

It is important to ensure that the specialist knowledge of dermatological care is passed on consistently, even in the case of personnel or organizational changes or new requirements at UHZ level.

The clinic’s nursing care focuses on three areas: dermatological specialist care, dermatology and palliative care.

Dermatological care is sometimes underestimated, but the fact is that nowadays patients are increasingly treated if possible outside of the hospital, and our most complex cases are multimorbid patients. This brings great but exciting challenges for the team, especially since the treatments are often interdisciplinary.

Another example of interdisciplinarity is extracorporeal photopheresis (ECP): we treat about 40 lung transplant patients with ECP annually. After the approval was given for treatment of lung transplant rejection in autumn 2016, we had to buy a third ECP device due to the increasing demand. These highly multimorbid patients are treated by our team in close cooperation with UHZ’s pneumology department.

Several nurse-based educational activities have been developed in the allergology unit, including specific training in the management of atopic dermatitis and allergic asthma. K. Grando is a highly skilled expert in adult patient education and has introduced the micro-education approach, which is now applied to all patients who receive allergen-specific immunotherapy.

Our outpatient care under the management of S. BeelerTrüssel has been intensively involved in the preparations for the move of the entire outpatient Department of Dermatology to the future location UHZ Airport.

13

Laboratory facilities The laboratory facilities of the department are devoted to routine lab procedures and research. The department manages fully equipped dermatopathology, allergology, mycology and serology/venereology labs, and eight competitive skin disease and allergy research labs.

Dermatopathology Our dermatopathology team examines and diagnoses 30,000 samples per year and provides sample testing for formalin-fixed tissue and cryomaterial (frozen section), and specific immunopathological studies (immunohistochemistry, immunofluorescence). In collaboration with other teams, we provide molecular biological studies (PCR) for pathogen search or suspicion of lymphomas.

Our dermatopathology is a certified teaching center and organizes regular courses in dermatology for residents in collaboration with the European Academy of Dermatology and Venereology (EADV).

Other routine laboratories The clinic is also equipped with laboratories devoted to allergology, molecular diagnostics, mycology and syphilis

serology. These labs are run under the laboratory head Dr P. Bosshard (together with Prof. P. Schmid-Grendelmeier in the allergology laboratory) and together they analyze 12,000 patient samples a year. The allergology lab was among the first to use ISAC (Immuno Solid-phase Allergen Chip) in Switzerland. In molecular diagnostics, tests such as the T cell receptor clonality assay or a genital ulcer disease multiplex PCR are performed. The mycology lab is renowned as a reference laboratory, in particular for dermatophyte infections. The routine labs are fully accredited according to ISO 15189:2012.

Research laboratories The continued expansion of our research activities with about 50 researchers was matched by an expansion of our research space. We now operate research laboratories on the top floor of our department at Gloriastrasse 31, as well as in two research buildings at the new biomedical campus in Schlieren – Wagistrasse 12 and 14. The latter labs contain state-of-the-art equipment in order to perform competitive research in the fields of biochemistry, molecular biology, cell biology, immunology and allergy. For animal experiments, we have access to a modern animal house at UHZ, as well as in Schlieren. Our research labs are certified according to ISO standards and comply with GMP guidelines for patient samples.

Financial Key-Facts 2015

2016

Change % (2015–2016)

Number of Leaves in Inpatient Clinic

2014

1346

1284

1344

4.7%

Number of Patient-Days in Bed-Clinic

10,416

11,016

10,398

-5.6%

Duration of stay of Inpatients (average)

6.5

7.3

6.4

-12.3%

Casemix-Index

0.904

1.000

0.947

-5.3%

Taxpoints (outpatient setting in thousand)

16,568

17,009

17,681

4.0%

Number of Outpatients

21,955

21,965

22,594

2.9%

Consultations outpatient setting

71,834

71,201

70,844

-0.5%

Revenues (medical service in thousand)

39,951 47,262 51,914

30,469 28,849 30,212

9.8%

Biopsies Dermatopathology

14

4.7%

5 Quality Management

Main fields of activity Our aim is to ensure that our organization and services are consistent and of the best possible quality. Our activities can be divided into four main components: quality planning, quality control, quality assurance and quality improvement. Our activities not only focus on service quality, but also on the means to achieve it. Our quality management therefore uses quality assurance and control of processes, such as PDCA (plan-do-check-act or plan-do-check-adjust) to achieve more consistent quality.

In order to achieve this goal, we intentionally chose a multidisciplinary approach to reach out to all groups of professions and break barriers between those groups.

Quality Management Team

Dr Mirjam Nägeli Responsible for Medical Aspects Physicians

Our main focus of interest is the permanent improvement of the quality of care, the safety of our patients and the satisfaction of our collaborators, referring physicians and, most importantly, patients.

Analysis of patient feeback indicates that more than 98% of all patients would recommend us to a friend or a relative, and 99.5% would choose to be treated again at our faculty.

We cover topics such as complaint management, Critical Incident Report System (CIRS) and surveys (patients, collaborators and referring physicians). One of the central activities is the analysis and critical appraisal of all processes in the institution. In order to improve the standard of care, we introduced a quality manual that is reviewed and updated on a regular basis. We use quality assurance and process control to achieve, maintain and permanently improve the quality of our care. We formulate annual goals, and execute and monitor them using an interdisciplinary approach that breaks down barriers and involves all collaborators in the process. The department is ISO 9001: 2008 certified by Swiss TS since 2011. This certificate covers the clinic, research, education and our laboratories.

Our skin cancer center has been certified by the Deutsche Krebsgesellschaft (DKG) via Onkozert since 2011.

We are in charge of the certifications, but consider the real challenge is to make the step from simply fulfilling requirement catalogs to real quality management projects where everyone (collaborators, patients and referring physicians) can feel the improvement.

Dr Joanna Mangana Responsible for Medical Aspects Physicians

Heiko Müller Responsible for Aspects of Nursing

Prof. Ralph Braun Head team quality management Department of Dermatology

15

6 Research

We aim to continuously improve the quality of our service for patients and we are committed to the highest level of research in dermatology. Our achievements in this field – as judged by the cumulative impact factors for 2014 and 2015 (561 and 918) – position us among the world’s leading departments.

Our research activities focus primarily on basic, patientoriented translational and clinical research in dermato-oncology, where we focus on the pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly in melanoma, cutaneous lymphoma and non-melanoma skin cancers. Immunodermatology is also a research focus, in particular innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions and severe allergic adverse drug reactions. Allergology focuses on atopic dermatitis, drug and food allergies, and specific immunotherapy.

16

The aim of our research activities is to:

promote high quality research with clinical relevance in the defined fields of focus.

promote intensive networking and collaboration with other institutes and departments at the University of Zurich and ETH, and through active participation in networks such as Cancer Network Zurich and Life Science Zurich.

support fellowships abroad in excellent research institutions and maximize competitive research funding, including that from the Swiss National Science Foundation (SNF professorships). create endowed professorships in our depart - ment in inflammatory skin disease and skin cancer research, with the aim of recruiting and retaining leaders in these research fields.

Key figures and highlights Approximately 40 clinical trials on new therapeutic approaches in skin disease are ongoing – corresponding to about 15% of all studies performed at UHZ. In 2015, our department published more than 100 original research articles and approximately 20 reviews in peer-reviewed journals.

Several original publications in interdisciplinary journals, such as: Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP, Dummer R, Goldinger SM. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. Br J Dermatol 2016;174:823-30 Maul JT, Djamei V, Kolios AGA, Meier B, Czernielewski J, Jungo P, Yawalkar N, Mainetti C, Laffitte E, Spehr C, Anliker M, Streit M, Augustin M, Rustenbach S, Conrad C, Hafner J, Boehncke WH, Borradori L, Gilliet M, Itin P, French LE, Häusermann P, Navarini AA. Efficacy and survival of systemic Psoriasis treatments – an analysis of the Swiss registry SDNTT. Journal of Dermatology 2016 “Dermatology (Basel, Switzerland).” Dermatology. Jan 12. [Epub ahead of print] Maul JT, Kretschmer L, Anzengruber F, Pink A, Murer C, French LE, Hofbauer GF, Navarini AA. Impact of UVA on pruritus during UVA/B-phototherapy of inflammatory skin diseases – a randomized double-blind study. J Eur Acad Dermatol Venereol 2016 Oct 4.

[Epub ahead of print]

Mehra T, Ikenberg K, Moos R, Benz R, Nair G, Schanz U, Haralambieva E, Hoetzenecker W, Dummer R, French L, Guenova E, Cozzio A. Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sézary Syndrome JAMA Dermatol.

2015 151(1): 73-7 Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, GuttmanYassky E, Hoetzenecker W, Knol E, Simon HU, Wollenberg A, Bieber T, Lauener R, Schmid-Grendelmeier P, Traidl-Hoffmann C, Akdis CA. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336-49

SSS Weekend Our 20th and 21st SSS (Science, Sun and Snow) weekend took place again in 2015 and 2016. Approximately 50 researchers participated in this meeting, which was held in the Schatzalp Hotel in Davos. For one and a half days, our young researchers presented their work and updates of their progress, followed by intense discussions. The meeting also allowed a ski day, a dinner and a fondue evening, creating an ideal atmosphere for scientific exchange.

918

Impact Factor per Year

808 780 632 120

487

100

469 467

561

355 80

60

312 190

40

20

0

Research Articles Reviews 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

17

Research groups

Prof. Barbara Ballmer-Weber, MD Group Members and Associates Caroline Guillod, MD Clauda Lang, MD Nora Gräni, MD Muriel Trächsler

Main Fields of Research Our research activities are focused on food allergy, in particular pollen related food allergy. We are particularly involved into the identification and molecular characterisation of important cross-reactive allergens, and the development of diagnostic and therapeutic methods based on recombinant allergens. Allergen based on component resolved diagnosis in food allergy is a major topic of our research group. Another important aspect of our research activity is risk assessment in food allergy with regard to genetic modified foods/novel foods but also threshold doses (minimal allergen doses to induce an allergic reaction) of plant and anmimal food allergens.

Selected References Ballmer-Weber BK, Brockow K, Fiocchi A, Theler B, Vogel L, Ring J, Szépfalusi Z, Mazzina O, Schaller R, Fritsché R, Vissers YM, Nutten S. Hydrolysed egg displays stron decrease in allergenicity and is well-tolerated by egg allergic patients. Allergy 2016; 71:728-32 Ballmer-Weber BK, Fernandez-Rivas M, Beyer K, Defernez M, Sperrin M, Mackie AR, Salt LJ, Hourihane JOB, Asero R, Belohlavkova S, Kowalski M, de Blay F, Papadopoulos NG, Clausen M, Knulst AC, Roberts G, Popov T, Sprikkelman AB, Dubakiene R, Vieths S, van Ree R, Crevel R, Mills C. How much is too much? Threshold dose distributions for five food allergens. J Allergy Clin Immunol.

JACI 2015; 135: 964-71 Ballmer-Weber BK, Skamstrup Hansen K, Sastre J, Andersson K, Bätscher I, Ostling J, Dahl L, Hanschmann KM, Holzhauser T, Poulsen LK, Lidholm J, Vieths S. Component-resolved in vitro diagnosis of carrot allergy in three different regions of Europe.

Allergy 2012; 67(6): 758-66 Mackie A, Knulst A, Le TM, Bures P, Salt L, Mills ENC, Malcolm P, Andreou A, Ballmer-Weber BK.High fat food increases gastric residence and thus thresholds for objective symptoms in allergic patients. Mol Nutr Food Res 2012, 56:1708-14 Bublin M, Pfister M, Radauer C, Oberhuber C, Bulley S, Dewitt AM, Lidholm J, Reese G, Vieths S, Breiteneder H, HoffmannSommergruber K, Ballmer-Weber BK. Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens.J Allergy Clin Immunol 2010;125:687-94

18

PD Hans-Dietmar Beer, PhD Group Members and Associates Gerhard Strittmatter, PhD Martha Garstkiewicz, PhD Jennifer Sand Serena Grossi

Main Fields of Research Keratinocytes represent the main cell type of the epidermis. This outermost layer of the skin is directly exposed to numerous types of stress. Our research tries to elucidate the mechanisms, which are responsible for the maintenance of the integrity of the epidermis under stress conditions. Protein complexes, termed inflammasomes, and the protease caspase-1, which is their central molecule, play important roles in these processes, including sunburn, infection by Herpes virus and UV-induced skin cancer development. Since these defence mechanisms are only poorly conserved in other species, such as in mice, we are establishing novel protocols for the stable genetic manipulation of human primary keratinocytes and of skin cancer cells. In addition, we are interested in understanding how anti-inflammatory drugs modulate inflammasomes and caspase-1.

Selected References Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression. Garstkiewicz et al., Eur J Immunol. 2016, eji.201646665 [Epub ahead of print] IFN-γ primes keratinocytes for HSV-1-induced inflammasome activation Strittmatter et al., J Invest Dermatol. 2016, 136, 610-20

19

Research groups

Philipp P. Bosshard, PhD and Martin Glatz, MD Group Members and Associates Cheryl Leong Kit Mun, PhD Bettina Schmid, PhD student Ksenia Mischler, MD student Antonino Buttafuoco, MSc Riccardo Curatolo, MSc student Nada Juricevic, technician

Main Fields of Research Our research activities focus on skin infections and pathogen-host-interactions. This comprises research on bacterial infections (e.g. sexually transmitted infections), fungal infections and the role of the human skin microbiome in inflammatory skin diseases such as atopic dermatitis. Our main interests are epidemiological studies, to develop and improve diagnostic tools for skin infections (e.g. PCR) and to perform research on the human skin microbiome (e.g. next generation sequencing).

Selected References Arora N, Schuenemann VJ, Jäger G, Bosshard PP et al. Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster. Nat. Microbiol. 2016;2:16425 Glatz M, Bosshard P, Schmid-Grendelmeier P. The Role of Fungi in Atopic Dermatitis. Immunol Allergy Clin North Am [Epub ahead of print] Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, Kong HH, Amagai M, Nagao K. Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis. Immunity. 2015;42:756-66 Glatz M, Means T, Haas J, Steere AC, Müllegger RR. Characterization of the early local immune response to Ixodes ricinus tick bites in human skin. Exp Dermatol 2016. [Epub ahead of print]

20

Prof. Ralph Braun, MD Group Members and Associates Sabine Ludwig Sarah Denzler Corinne Eggenschwiler Severin Marfurt Aline Golliez Sophie Gu

Main Fields of Research Our main interest is the non invasive diagnosis of skin cancer, especially malignant melanoma. We use established techniques such as dermoscopy as well as new techniques including in vivo laser scanning microscopy.

Due to different international research collaborations our patients benefit directly from the latest technological developments.

Selected References Dummer R, Ramelyte E, Levesque M, Goldinger SM, Braun RP. Critical aspects to achieve a high-quality melanoma clinic.

Curr Opin Oncol 2017; 29:145-150 Scope A, Braun RP. The Recognition Process in Dermoscopy: Analytic Approach vs Heuristic Approach. JAMA Dermatol 2015;151:704-706 Jaimes N, Marghoob AA, Rabinovitz H, et al. Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin. J Am Acad Dermatol 2015;7:1027-1035

21

Research groups

Prof. Reinhard Dummer, MD Group Members and Associates Prof. Mirjana Maiwald, MD Prof. Mitchel Levesque, MD Joanna Mangana, MD PD Simone Goldinger, MD Marieke Raaijmakers, MD Phil Cheng, Ph.D Daniel Hug Egle Ramelyte Valerie Amann Jil Dreier

Main Fields of Research The team has established a world class skin cancer center providing the best clinical care connected to translation and clinical research. We intensively investigate the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with best quality of life.

Selected References Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016;375:1845-1855 Shain Hunter A, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D’Arrigo C, Robson A, Path FRC, Bastian BC. The Genetic Evolution of Melanoma from Precursor Lesions: N Engl J Med 2015;373:1926-36 Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, on behalf of the ESMO Guidelines Committee, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:126-132 Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis K, Combermale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomized, double-blind phase 2 trial. Lancet Oncol 2015;16:716-28

22

Prof. Lars E. French, MD Group Members and Associates Emmanuel Contassot, PhD Takashi Satoh, PhD Mark Mellett, PhD Deepa Mohanan, PhD Barbara Meier, MD Charlotte Brüggen, MD, PhD Betina Kiefer Gabriele Fenini Roman Huber

Main Fields of Research Our skin is not only a physical barrier against the environment but also an immunologically active organ, which can readily respond. Cutaneous inflammation is a very common condition in dermatology and numerous insults from the environment or endogenous danger signals can lead to skin inflammation. The aim of our research is to better understand the molecular events leading to inflammatory responses in the skin. We are particularly interested in the mechanisms involved in i) the immune responses to Propionibacterium acnes in acne vulgaris; ii) hypoxia-induced melanoma progression; and iii) the regulation of the danger- and pathogen-sensing intracellular complexes known as inflammasomes in keratinocytes. We found that i) Propionibacterium acnes can induce mixed Th1/Th17 responses in the skin of acne patients ii) in hypoxic conditions, melanoma cells secrete the alarmin HMGB1 inducing the accumulation of tumor-promoting macrophages; and iii) the regulation of the inflammasomes in keratinocytes upon UVB exposure is different to that seen in myeloid immune cells. The new pathways, cell types and cytokines involved in the above-mentioned inflammatory skin diseases present as potential targets for the development of new therapies.

Selected References Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Kabashima K, Nonomura Y, Dummer R, Contassot E, French LE. Tumor hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Sci Rep 2016;6:29914 Kistowska M, Meier B, Proust T, Feldmeyer L, Cozzio A, Kuendig T, Contassot E, French LE. Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. J Invest Dermatol 2015;135:110-8

23

Research groups

PD Emmanuella Guenova, MD, PhD PD Antonio Cozzio MD, PhD Group Members and Associates PD Wolfram Hötzenecker, MD, PhD Joanna Mangana, MD Tabea Koch, MTA diagnostic Agathe Duda, MTA diagnostic Desislava Ignatova, PhD student Yung-Tsan Chang, PhD student Pesho Ivanov, PhD student Ieva Saulite, MD student Tanja Eberle, MD student

Main Fields of Research Our research activities focus on (i) interactions between innate and adaptive immunity in cutaneous inflammation; (ii) pathogenesis and therapy of skin tumours; cutaneous lymphoma & Merkel cell carcinoma; (iii) development of new immune therapies and translational research.

Selected References Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell 2015;162:1242-56 Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Köberle M, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark RA, Röcken M, Biedermann T. IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells.

Proc Natl Acad Sci U S A. 2015;112(7):2163-8. IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA 2015;112:2163-8

24

Prof. Jürg Hafner, MD Group Members and Associates In-Hospital Dermatology: Prof. Mirjana Maiwald, MD; Mirjam Nägeli, MD Surgical Dermatology: PD Severin Läuchli, MD; Sabine Bruckert, MD; Stephan Nobbe, MD Vascular Medicine and Wound Healing: PD Benedikt Weber, MD, PhD; PD Nikolaus Duschek, MD, PhD; Claude Luder, MD; Caroline Buset, MD

Main Fields of Research Dermatology in severely ill patients Dermatologic surgery and surgical oncology Dermatology in immunosuppression Dermatologic angiology and phlebology Wound healing

Selected References Feldmeyer L, Bogdan I, Moser A, Specker R, Kamarashev J, French LE, Läuchli S: Short- and long-term efficacy and mechanism of action of tumescent suction curettage for axillary hyperhidrosis. J Eur Acad Dermatol Venereol 2015;29:1933-7 Hafner J: Calciphylaxis and Martorell hypertensive ischemic leg ulcer: same pattern – one pathophysiology.

Dermatology 2016;232:523-533 Hafner J, Läuchli S, Bruckert S, Nobbe S, Möhrle M, Löser C: Split skin graft “from scalp-to-scalp” to repair large surgical defects.

JDDG 2015;13:937-940 Hafner J, Möhrle M, Löser C: Retroauricular pedicled flap for repair of large helix and anthelix defects. JDDG 2016;14:753-755 Luder C, Dziunycz P. Omid N, Radetzki AL Lang C, Hübner M, Hafner J: A compression kit of a stocking and three superimposed leggings is easy to don and dose adjustable. Eur J Vasc Endovasc Surg 2016;51:434-440 Skrinjar E, Duschek N, Bayer GS, Assadian O, Koulas S, Hirsch K, Basic J, Assadian A: Randomized controlled trial compraring the combination of a polymeric membrane dressing plus negative pressure wound therapy against negative pressure wound therapy alone: The WICVAC study Weber B, Hafner J, Willenberg T, Hoerstrup SP: Bioengineered valves for the venous circulation. Expert Rev Med Devices.

2016 Nov;13(11):1005-1011

25

Research groups

Prof. Thomas M. Kündig, MD Group Members and Associates Prof. Martin Bachmann, PhD Prof. Gabriela Senti, MD ° Johansen, PhD PD Pal PD Steve Pascolo, PhD PD Ying Waeckerle-Men, PhD Gary Jennings, PhD Anja Fettelschoss, PhD Franziska Thoms Zabel Florian Olomski Stefanie Haas Anna Wiegand Corinne Zurfluh

Main Fields of Research Our research group is focused on immunotherapy of allergies and cancer. In allergy we aim to improve and shorten current regimens for immunotherapy or desensitization, which today require 3 to 5 years of allergen administration. We found that direct administration of allergen into a lymph node allowed shortening immunotherapy from 60 to merely 3 injections. Also, we developed epicutaneous immunotherapy, where allergens are applied by use of a skin patch, shortening a course of treatment to merely 6 patch applications. Using virus-like particles we aim to further reduce the number of allergen applications to one or two. We are also using virus-like particles for anti-cytokine vaccination in horses and dogs, and furthermore in cats to render them hypoallergenic. In cancer we focus on the role of cytokines in tumor cachexia and we are working RNA-based cancer vaccines.

Selected References Bachmann MF, Kündig TM. Allergen-specific immunotherapy: is it vaccination against toxins after all? Allergy 2016.

[Epub ahead of print] Senti G, Kundig TM. Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and Intradermal.

Immunol Allergy Clin North Am 2016;36:25-3

26

Prof. Mitch Levesque, PhD Group Members and Associates Ossia Eichhoff, PhD Phil Cheng, PhD Anja Irmisch, PhD Gaetana Restivo, PhD Annalisa Saltari, PhD Marieke Raaijmakers, MD Melanie Maudrich Theodora Chatziisaak Alice Langer Betina Kiefer Sabrina Schindler Ishani Banik

Main Fields of Research Our research interests are in understanding the molecular mechanisms of melanoma progression and identifying novel biomarkers or targets that may be translated into clinical practice. We also run the dermatology biobank, which is a critical resource for basic research as well as translational oncology. Please visit our website for more information: www.cnz.uzh.ch/en/Research/RG3/Levesque.html

Selected References Raaijmakers MIG, Widmer DS, Narechania A, Eichhoff O, Wenzina J, Cheng P, Mihic-Probst D, Desalle R, Dummer R, Levesque MP. Co-existence of BRAF and NRAS Driver Mutations in the Same Melanoma Cells Results in Heterogeneity of Targeted Therapy Resistance. Oncotarget 2016;7:77163-77174 Smith MP, Brunton H, Rowling, E Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper, ZA, Wargo JA, Wellbrock C. Inhibiting drivers of non-mutational drug-tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell 2016; 29:3:270-284 Cheng, PF, Shakhova, O, Widmer, DS, Zing, D, Benedetta B, Raaijmakers, MMI Eichoff OM, Goldinger SM, Hemmi S, Hoek KS, Sommer L, Dummer R, Levesque MP. Methylation dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology 2015;6:42 Raaijmakers MIG, Widmer DS, Maudrich M, Koch T, Langer A, Flace A, Schnyder C, Dummer R, Levesque MP. A new live cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology 2015;24:377-80

27

Research groups

Prof. Alexander Navarini, MD, PhD Group Members and Associates Rebecca Higgins, PhD Adhideb Ghosh, PhD Florian Anzengruber, MD univ.

Mathias Drach, MD univ.

Moritz Klinger, M.Stud.

Katja Hofstetter, M.Stud.

Associated members (from Inflammatory Dermatoses Study Team and Patch Test Unit) Tamsyn Meyer Julia Püschel Jasmine Narainsing

Main Fields of Research The focus of our activities is the investigation of inflammatory skin disease, especially neutrophil-mediated inflammatory dermatoses (NMID). We have two groups of investigators working on projects addressing genetic and pathophysiological questions (NMID-Team), as well as a newer and smaller Vision-Team whose aim is to transform visual information into quantifiable phenotypic data.

Selected References Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M. Vedolizumab as a successful treatment of CTLA-4associated autoimmune enterocolitis. J Allergy Clin Immunol 2016. [Epub ahead of print] Maul JT, Kretschmer L, Anzengruber F, Pink A, Murer C, French LE, Hofbauer GF, Navarini AA Impact of UVA on pruritus during UVA/B phototherapy of inflammatory skin diseases: a randomized double-blind study. J Eur Acad Dermatol Venereol. 2016 [Epub ahead of print]

28

PD Steve Pascolo, PhD Group Members Pantelyushin Stanislav, PhD, Postdoc Marina Tusup, PhD Student Associated members (from URPP “Translational Cancer Research”) Prof. Maries van den Broek, PhD Prof. Burkhard Becher, PhD Prof. Michael Weller, MD Prof. Onur Boyman, MD

Main Fields of Research Our major focus of research is the therapeutic utilization of RNA. We develop multifunctional anti-cancer immunostimulating RNA formulations. Within the University Research Priority Program (URPP) “Translational Cancer Research”, we generate and formulate mRNA for expression of therapeutic proteins. As we have done in the past, those RNA-based strategies can be transferred to clinics and tested in clinical trials.

Selected References Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Brossart P,.Pascolo S. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology 2015: 5:5 Pascolo S. The messenger’s great message for vaccination. Expert Rev Vaccines 2015;14:153-6

29

Research groups

Prof. Peter Schmid-Grendelmeier, MD Group Members and Associates Benno Schnyder, MD Eugen Bersuch, MD Meike Distler, MD Matthias Drach, MD Kirsten Schiesser, MD Christina Weber, MD Celine Eichenberger Karin Grando Karin Schnyder Muriel Träxler

Main Fields of Research Our research activities are focused on epidemiology, pathophysiology and treatment of allergic diseases, namely atopic dermatitis. We also investigate new therapeutic options in a variety of diseases, mainly atopic dermatitis, mastocytosis and drug allergy. Recently we have also started to implement, evaluate and improve educational tools to promote knowledge and training in allergic diseases.

Selected References Allergic Skin Diseases. Ong PY, Schmid-Grendelmeier P. Immunol Allergy Clin North Am 2017 Feb (Book) Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, Hoetzenecker W, Knol E, Simon HU, Wollenberg A, Bieber T, Lauener R, Schmid-Grendelmeier P, Traidl-Hoffmann C, Akdis CA. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.J Allergy Clin Immunol 2016; 138:336-49 Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, Jutel M, Ong PY, Poulsen LK, Schmid-Grendelmeier P, Simon HU, Seys SF, Agache I.Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitisPRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016;137:1347-58 Abramson MJ, Schindler C, Schikowski T, Bircher AJ, Burdet L, Gerbase MW, Imboden M, Rochat T, Schmid-Grendelmeier P, Turk AJ, Zemp E, Künzli N, Probst-Hensch N. Rhinitis in Swiss adults is associated with asthma and early life factors, but not second hand tobacco smoke or obesity. Allergol Int 2016;65:192-8

30

PD Lisa Weibel, MD Group Members and Associates Martin Theiler, MD Agnes Schwieger, MD Regula Wälchli, MD Barbara Heidecker, MD PD Clemens Schiestl, MD Katharina Steindl, MD Dr phil Ornella Masnari

Main Fields of Research Our research group is based at UHZ and the University Children’s Hospital. Our activities focus on rare skin disorders, congenital anomalies, stigmatization and pediatric clinical drug studies. As for rare skin disorders we are investigating the genetic background of localized scleroderma (with Prof. A. Navarini, Zurich), hair disorders such as uncombable hair syndrome and others (with Prof. R. Betz, Köln), the inflammatory profile of Netherton syndrome (with Prof. A. Hovnanian, Paris), aspects of congenital melanocytic nevi (with Dr. V. Kinsler, London) and we detect new types of epidermolysis bullosa (with Prof. C. Has, Freiburg). We perform clinical studies with patients with vascular anomalies such as infantile hemangioma including the description of topical betablocker therapy and the publication of European and national treatment Guidelines. As for complex vascular disorders we investigate PIK3CA-related overgrowth syndromes and the clinical response to treatment with sirolimus (orphan disease indication). As the only Swiss pediatric center we participate in international drug trials for the treatment of psoriasis.

Selected References Weibel L, Barysch MJ, Scheer HS, Königs I, Neuhaus K, Schiestl C, Rentsch K, Müller DM, Theiler M. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol 2016; 33:184-90 Leclerc-Mercier S, Bodemer C, Furio L, Hadj-Rabia S, de Peufeilhoux L, Weibel L, Bursztejn AC, Bourrat E, Ortonne N, Molina TJ, Hovnanian A, Fraitag S. Skin biopsy in Netherton syndrome: a histological review of a large series and new findings. Am J Dermatopathol 2016; 38:83-91

31

7 Clinical Research: The University Hospital Zurich Dermatology Clinical Trial Unit

Clinical research is a major focus in an academic center like ours. It is essential to translate new basic research results into beneficial treatment regimens. Clinical trials today are performed in an increasingly regulated network that combines clinical, ethical, legal and economic aspects. Respect for the patient’s life and well-being, and the integrity of all personnel involved (principles of good clinical practice) are absolutely central. A network of clinical trial specialists is necessary in order that clinical trials can be integrated in the treatment strategy for the respective disease.

The Department of Dermatology and the skin cancer unit have a long and successful record in this context. We are a major research center for the development of targeted therapy and immunotherapy for skin cancers and immune-mediated skin diseases.

The clinical trial unit of our center has extensive experience in early and late phases of clinical development (phase I-IV). The unit is certified by SAKK to perform phase I trials and offers a post-graduate education in pharmaceutical medicine. In addition, the unit recently received permission for its own trial pharmacy. Dedicated trial pharmacists have joined the team and established pharmaceutical management to further improve quality for our trial patients.

32

In recent years, the clinical trial unit has worked with many molecules including: BRAF-inhibitors MEK-inhibitors – Combination therapies with other kinase inhibitors including ribociclib Anti-CTLA-4 antibodies Anti-PD1 antibodies – Combination of different immunotherapy agents including epacadostat and T-VEC – Oncolytic virus therapy with T-VEC – Pan-RAF inhibitors including RAF265, LXH254 MDM2 inhibitors Somatostatin-analogons Antisense-BCL-2 Nucleotides Tyrosine kinase inhibitors including nilotinib, pazopanib, lapatinib and sorafenib Gene therapy including T Vec Allovectin-7 and adenointerferon gamma and canary pox viral vectors Pan-kinase and Anti-VEGF inhibitors Monoclonal antibody-cytokine fusion proteins Vaccines Antimicrobial agents (taurolidine) PEG interferon Various Chemotherapies Hedgehog Pathway Inhibitors Histone-Deacetylase Inhibitors (HDAC) RXR Retinoids NAD+ biosynthesis inhibitors Purine Nucleosid Phosphorylase inhibitors Resiquimod IL-17A and IL-17R antibodies PDE4 inhibitors TNF-α antagonists IL-12/23 antibodies IL-1β antagonists IL1Ra soluble receptor Topical parathormone Topical Vitamin D3 analogons Anti-IgE antibodies

Director Clinical Trial Unit of the Department of Dermatology PD Simone M. Goldinger, MD (group leader) Quality management Séverine Buffoni Study nurses Karen Meyer, Michelle Arnold, Myra Wortmann, Alexandra Meyer, Daniel Steiner Pharmacists Joelle Dornbierer, Andreas Dzung, PD Dr Clemens Schiestl, MD Dr Katharina Steindl, MD, Dr phil Ornella Masnari Study coordinators Tamsyn Meyer, Julia Püschel, Jasmin Narainsing, Claudio Hümbelinn Study nurse assistant Ganimete Mjekiqi

We focus on the development of investigator initiated trials (IITs) for the treatment of orphan diseases of the skin and for sub-groups of skin cancer patients with high medical requirements, such as those with brain metastases.

Our clinical trial unit is today one of the leading clinical research centers in Europe Recognized as SAKK Phase I Center in September 12, 2016: the dermatological clinical trial unit UHZ was officially approved by the Swiss Association for Clinical Cancer Research (SAKK) to conduct SAKK Phase I/first in human (FIH) studies.

33

8 Research Collaborations

University Research Priority Program (URPP) Translational Cancer Research www.cancer.uzh.ch

Since the launch of the University Research Priority Program (URPP) for Translational Cancer Research in 2012, the Department of Dermatology has been an important contributing partner and has also greatly benefited from the interaction and financial support provided.

URPP Translational Cancer Research focuses on the following four sub-projects:

In 2012, the University of Zurich committed more than CHF 6 million over a period of four years in order to finance this URPP with the prime aim of bridging fundamental and clinical cancer research at the university.

The URPP is directed by Prof. L. French, along with vicedirector Prof. C. Basler and the scientific coordinator Prof. M. van den Broek.

2. Interaction between cancer and the immune system

The funding of URPP Translational Cancer Research clearly underscores the commitment of our university to the promotion of innovative cancer research and translation to the clinic through high quality science.

In 2015, the performance of URPP Translational Cancer Research was evaluated by three external experts commissioned by the university. Based on the very positive evaluation, productivity and outlook, in 2016 the University of Zurich decided to continue and increase the financing with an additional CHF 11 million for the next four-year period (2017–2020).

URPP Translational Cancer Research is unique in that it unites an exceptional team of internationally recognized scientists and physician-scientists in the field of oncology and cancer research, and is determined to bridge the gap in communication and collaboration between physicians and scientists to bring cancer research a step closer to translation into the clinic.

34

1. Oncogenic signal transduction pathways as targets for personalized tumor therapy

3. Tumor biopsy and live tumor cell biobank linked with clinical outcome data 4. Translation from bench to bedside

The project delivers innovation thanks to engaged post-doctoral fellows who liaise between clinical and basic labs and the high-level mentoring provided by the principal investigators in clinical and basic science. As a consequence of the above research strategy, an increasing number of interesting publications are appearing; an example is the collaborative work between the groups of Professors Sommer (Institute of Anatomy, University of Zurich), Levesque and Dummer (both Department of Dermatology, UHZ) on epigenetic control of melanoma growth and metastasis through silencing of distinct tumor suppressors by the epigenetic modifier EZH2 (Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, Shakhova O, Dummer R, and Sommer L. Nature Communications, 6:605, 2015).

Skintegrity – A flagship project on skin www.hochschulmedizin.ch/skintegrity

In autumn 2016, a new large-scale interdisciplinary project of Hochschulmedizin Zürich was initiated with the aim of establishing the Zurich location as a world-leading center for skin research. The project is led by S. Werner, Professor of Cell Biology at ETH, and L. French, Professor of dermatology and venereology at the University of Zurich and Director of the Department of Dermatology, UHZ. The main reason for the project is the increasing importance of skin diseases, such as skin cancer, chronic skin wounds and scleroderma. Through a unique collaboration

between highly specialized clinicians and scientists from the University of Zurich and ETH, the best expertise in biology, medicine, mechanics and engineering can provide the best basis for rapid and targeted research to improve the treatment of severe skin diseases.

We focus on the development of investigator initiated trials (IITs) for the treatment of orphan diseases of the skin and for sub-groups of skin cancer patients with high medical requirements, such as those with brain metastases.

Interactions between Sub-Project-Groups Skintegrity.

35

9 Collaborations with other Dermatology Centers Dermatological outpatient clinic at Kantonsspital Frauenfeld A dermatological outpatient clinic at the cantonal hospital in Frauenfeld (KSF) has been in operation since 2011 in close collaboration with the Department of Dermatology of UHZ. The clinic is run by two senior dermatologists from the Department of Dermatology of UHZ, who divide their hours equally between UHZ and KSF. A six-month rotation for senior dermatology residents from UHZ was started in 2013. Dr St. Nobbe, part of the team in Frauenfeld from the start, is officially heading the clinic since July 2015. The other senior dermatologists are currently Dr M. Barysch (April 2015–April 2016) and Dr L. Wiederkehr (since May 2016).

Dermatology team of KFS (left to right): Dr Marjam Barysch, Dr Stephan Nobbe, Anita Schaub, Dr Michael Kunz, Simone Varga

The clinic covers a broad spectrum of outpatient dermatology, including a radiotherapy unit. The majority of patients are referred by practicing physicians, from both primary carers and specialists. In addition, the clinic is responsible for dermatological inpatient consultations of all hospitals in the canton of Thurgau. Special consultation hours are held on a monthly basis with professors from UHZ. After five years of operation, the results are very positive and the outpatient clinic is a valuable addition to the dermatological services of the canton of Thurgau.

Center of Dermatology and Allergology, Luzerner Kantonsspital The cantonal hospital Lucerne comprises the central hospital in Lucerne, two primary healthcare hospitals at Sursee and Wolhusen, and the Lucerne Alpine Clinic

36

Montana. It is the biggest non-university central hospital in Switzerland. The Center of Dermatology and Allergy is responsible for the dermatological and allergological care of the population of central Switzerland. It is part of the Department of Medicine and has access to inpatient facilities with patients treated in the intensive care unit or the medical day clinic. It comprises a dermatological ambulance, an allergy ambulance and an allergy day clinic, covering the whole spectrum of outpatient dermatology and allergology, with about 25,000 outpatient contacts a year.

It is accepted as a dermatology training institution “B” offering a three-year curriculum to dermatology students.

The center is headed by Prof. Ch. Brand and his deputy Prof. B. Ballmer-Weber. The medical staff comprises the co-head physician Dr G. Müllner, the leading physician Dr A. Wysocki, three senior physicians, three consultants and three to four assistant physicians. There is close collaboration between the Department of Dermatology at UHZ and the Center of Dermatology and Allergology Lucerne, with allergy multicenter studies run at both locations by Prof.

B. Ballmer-Weber. An exchange of dermatology students between the two clinics is in discussion.

Kantonsspital St. Gallen Through our lymphoma consultation setting under the lead of PD Dr K. Kerl (UHZ) and PD Dr E. Guenova (UHZ, cantonal hospital of St Gallen), we treat one of the largest patient groups with cutaneous lymphomas in Europe.

This institution was recently extended as part of a collaboration with the Department of Dermatology and Allergology at the cantonal hospital of St. Gallen (KSSG). Patients from eastern Switzerland can be treated by Dr Guenova at KSSG. And thanks to the addition of Dr Guenova at UHZ, these patients can be offered the latest diagnostic and therapeutic procedures in clinical trials at KSSG. This service from both hospitals helps to offer the patient an optimal and individual care.

10 Research Collaborations – Associations and Foundations Bruno Bloch Foundation www.brunoblochstiftung.ch

One of the traditions and highlights at the Bruno Bloch Foundation are the yearly Memorial Lectures, which take place in February with more than 200 faculty members and students at UHZ. In 2015, the Bruno Bloch Memorial Lecture was held by Prof. Andreas Bircher, Chair Department of Allergology, University Hospital Basle, and in 2016 by Prof. Karin Scharffetter-Kochanek, Chair of the Department of Dermatology and Allergologic Diseases at Ulm University, Germany.

For the first time in 2013, the Bruno Bloch Foundation organized a charity recital with the exceptional contribution of Anne-Sophie Mutter. The funds collected served to finance research for skin diseases and skin cancer at the Department of Dermatology at UHZ. Important donators supported this charity evening and made a substantial benefit in favor of the research possible. Due to its success, the Bruno Bloch Foundation organized a second charity evening in November 2015 with the participation of soprano Edita Gruberova and the Zurich Chamber Orchestra (ZKO).

In 2015, the Board of Directors of the foundation decided to grant two fellowships each year to young dermatologists (residents) from the Department of Dermatology at UHZ for further training abroad.

As of 2016, selected guests were invited by the Bruno Bloch Foundation to attend the breakfast round table of the foundation. At this event, a representative of the medical staff of the Department of Dermatology at UHZ presented a specific topic of general interest in the field of dermatology to the audience.

The Bruno Bloch Foundation is also co-organizer of the Zürcher Dermatologische Fortbildungstage.

An important aim of the foundation is to foster fellow- ship – in 2016, Dr Lea Wiederkehr received a financial contribution for a residency in Trinidad.

Left to right: Michael Bühler, Managing Director Zurich Chamber Orchestra, Edita Gruberova, Patrick Schaffter, Administrative Director of the Bruno Bloch Foundation, Prof. Lars French, Alexander Valentovic, conductor

37

Report of the fellowship of Dr L. Wiederkehr: “In my last year…”

In my last year of residency I spent seven weeks abroad in Trinidad and Tobago at the Eric Williams Medical Science Complex Hospital. As Trinidad and Tobago has many inhabitants of Indian, Asian and African descent, the country is the ideal place to study skin of color. The staff around Dr Hallai gave me a very warm welcome and I quickly felt part of the team. During the morning we did ward rounds and in the afternoon we saw outpatients. It was remarkable to see these people waiting for hours for their appointment without complaining – very different from the behavior we sometimes see in Switzerland. On the weekend I had the opportunity to explore the country with its wonderful flora and fauna. Time flew by and I am grateful to the Bruno Bloch Foundation for supporting my exciting stay in Trinidad and Tobago. I obtained wide-ranging insight into the dermatology of skin of color, as well as into the daily life of a Caribbean island.

Association for Research on Cancer of the Skin (Verein für Hautkrebsforschung) www.skincancer.ch

The Verein für Hautkrebsforschung VHKF, association for research on skin cancer, founded in 2004, aims to coordinate and stimulate skin cancer research in Switzerland by supporting research of rare and severe forms of skin cancer (e.g. melanoma, cutaneous lymphoma).

The board consists of Prof. R. Dummer (President), Prof.

R. Braun, Prof. L. French, C. Frey-Blanc (Treasurer), all Zurich-based, Prof. D. Hohl (Vice-President), Lausanne, Prof. R. Hunger, Bern, Prof. R. Kaufmann, Frankfurt, and Prof. W. Kempf, Zurich. The current goal is to generate a substantial contribution to clinical and experimental skin cancer research in Zurich and in other institutions in Switzerland. Recently, the association created an assistant professor position at the University of Zurich. Prof.

M. Levesque, an internationally renowned melanoma researcher, will hold the position for at least four years starting from February 1, 2014. His research activities involve development of new tools for understanding next generation sequencing data, and functionally testing novel melanoma mutations in the lab. In this context, he is using the zebrafish model organism to better understand

38

the basic biology of cancer genes. In his new function, Prof. Levesque also manages the dermato-oncology biobank at UHZ, which provides a diverse collection of live cancer cells to collaborators for experimental research.

These are fundamental research activities that form the basis of an understanding of melanoma progression for future improvements in melanoma therapy.

In the past year, Prof. Levesque has also established a molecular tumor board for melanoma, with the help of the ETH Nexus platform and an innovation grant from UHZ. This will provide patients who have exhausted other therapy options with new possibilities based on the genomic sequence of their tumors and the availability of new targeted pathway inhibitors in the clinic. In addition, Prof.

Levesque obtained funding from the Skintegrity flagship project at ETH to continue expansion of the dermatology biobank and to make it more accessible to researchers across Zurich. Finally, collaboration with Roche and Bristol Myers Squibb has provided further funding to identify novel predictive biomarkers for melanoma immunotherapy treatment. These efforts have resulted in the submission of a manuscript in which novel features in the immune landscape of patients receiving anti-PD1 inhibitors were shown to be predictive of response. The molecular mechanisms of these observations will be further elucidated in the coming months and years.

k Dermatologische Klini

Skin Cancer Nurse ng für Beratung und Begleitu mit Hautkrebs.

Wir wissen weiter.

Patientinnen und Patie

nten

Financing of a new position: skin cancer nurse Although significant progress can be observed due to the variety of treatment strategies in metastatic melanoma within the last years, physicians and patients may have overlapping or divergent expectations of the outcome of cancer therapies and the quality of medical services.

However, hardly any communication takes place between physicians and patients about their interaction.

The nursing role during systemic therapy is particularly noteworthy. Since October 2016, a specialist skin cancer nurse, financed by the Verein für Hautkrebsforschung, has been integrated into the treatment processes and is responsible in particular for regular contact with patients regarding adverse events (AE), which can occur at any time during the treatment. Many patients find it easier to phone a nurse than a doctor; hence, nurses can provide open and easy contact to the treatment team. It is mandatory that the nurse is familiar with the peculiar AE spectrum and the timing of AEs during the therapy.

Christine Kühne Center for Allergy Research and Education (CK-CARE) The Christine Kühne Center for Allergy Research and Education (CK-CARE) is dedicated to the research and eduction of allergic diseases with a specific focus on atopic dermatitis. It has been initiated in 2009 with it’s domcile in Davos and is a network between research groups in Davos, Bonn, Munich, St. Gallen and the Allergy Unit Zurich (see www.ck-care.ch).

39

11 Medical Education and Teaching

Medical education is crucial to guarantee a high level of professionalism of physicians and healthcare professionals. Our continued implication in education is reflected by: 1. Student education in the medical faculty of the University of Zurich.

2. Specialist training for resident physicians qualifying in dermatology and venereology, and allergology and clinical immunology.

3. Continuing medical education for private practitioners – mainly dermatologists and allergologists, but also general practitioners and to a lesser extent other healthcare professionals.

Student education Senior physicians in our department provide an introductory dermatology course to third-year medical students, a yearly core course in dermatology (eight-day block) to fourth-year medical students, a case-based thematic lecture series in the sixth year, and a practical training course in dermatology in the sixth year of the medical training curriculum at the University of Zurich. In complement to these ex-cathedra and bedside teaching activities, medical students can benefit from web-based learning with an online platform (DOIT: Dermatology Online with Interactive Technology) developed by our department under the direction of former chairman, Prof.

Gunter Burg in close collaboration with several other dermatology departments (Basel, Bern, Lausanne, Jena, Stadtspital Triemli in Zurich, and the European Dermatology Forum; see also www.cyberderm.net).

This platform has been continuously improved under the new direction of Prof. Peter Itin with support of the European Dermatology Forum and currently exists in seven languages with two further languages scheduled. In 2009, the DOIT platform was chosen as the best internet-based teaching platform and won the EUR 50’000 Medida Prize.

Resident physicians The Department of Dermatology offers 22 residency positions for the five years of obligatory training required for Swiss board certification in dermatology. Demand for residency training in our department is extremely high,

40

with more than 150 applications for approximately four positions per year. Two training positions are also available for part of the board certification in immunology and allergology, and angiology. During their residency training in our department, residents benefit from the broadest offer in Switzerland, comprising a rotation plan through 20 units and specialist clinics covering all sub-specialties of dermatology and allergology, including dermato-oncology, autoimmune skin disease, trichology (hair disease), dermatosurgery, dermatopathology, physical skin therapy (radiotherapy, UV therapy, laser), phlebology and others.

In addition, three residency positions for board certification in allergology and clinical immunology are available on the allergy unit, counting for the full three years necessary in a specialist clinic to obtain the FMH qualification. The quality of the training and teaching receives a very high rating among residents.

Following interest from the German, Austrian and Swiss dermatological societies, the online platform for students (DOIT) is now being used as the basis for the development of a pan-European post-graduate online continuing medical education (CME) platform, to be named DERMOKRATES. Our department and faculty are actively participating in this innovative project.

The Department of Dermatology UHZ received FMH acknowledgment and confirmation on August 8, 2016, as a training center for pharmaceutical medicine (cat. A, three years) from September 28, 2015, with a satisfactory FMH visit on April 7, 2016, and FMH confirmation.

Continuing medical education and post-graduate training for private practitioners Our department and faculty offer 12 to 14 CME events and grand rounds per year, comprising six half-day thematic CME events per year at the University of Zurich Irchel (180–200 participants), and six to eight grand rounds and interdisciplinary CME sessions, the latter co-organized with other medical disciplines at UHZ. In addition, and as of 2007, four new CMEs per year entitled Dermatology Update have been added to our post-graduate teaching program, with the aim of providing a further platform for case presentations, short updates and an overview of important new publications in dermatology (Journal Club).

In addition, in the context of the new Schwerpunkt Entzündliche Hautkrankheiten, founded in 2013, in 2013 and 2014 our department organized four workshops on psoriasis for private practitioners (speakers: Prof. Lars French, Dr Antonio Kolios and Dr Julia-Tatjana Maul). In order to promote support for Medical Practitioner Assistants (MPA), four workshops took place under the lead of Dr Antonio Kolios and Dr Julia-Tatjana Maul. The aim of these is to optimize support for MPAs through, for example, preparation of the PASI score for patients in advance before consultation with the practitioner.

An interesting and interactive exchange motivates us to continue this concept of medical education at a broader level.

Guest Speakers 2015/2016 Speaker

Institution Topic

Ascierto Paolo, Prof.

National Cancer Institute,

How to apply immunotherapy in melanoma

Naples, IT

Dermatologie und Allergologie,

Session Praktische Tipps und Tricks:

Kantonsspital St. Gallen, CH

Clinical Pearls

Augustin Matthias, Prof.

Dermatologikum Hamburg, DE

Evidenzbasierte Therapie der Nagelpsoriasis

Beck Bernhard, MD

Private Praxis in Zürich,

Hautinfektionen beim Reiserückkehrer

Anliker Mark, MD

Tropen- und Reisemedizin am Bellevue, CH Biedermann Tilo, Prof.

Head Department of

Mikrobiom und atopisches Ekzem

Dermatology and Allergology,

TUM Munich, DE Bircher Andreas, Prof.

Head Department of

Das Kontaktekzem – immer ein immunologisches

Allergology, University Hospital

Phänomen?

Basle, CH Bischoff-Ferrari Heike, Prof.

Borradori Luca, Prof.

UniversitätsSpital Zürich,

Geriatrische Dermatologie: Grundlagen Healthy

Zentrum Alter und Mobilität, CH

Aging

Department of Dermatology,

Bullöse Dermatosen

Inselspital Bern, CH Borelli Siegfried, MD

Dermatologisches

Allergologie in der Dermatologischen Praxis

Ambulatorium des Stadtspitals

Triemli, Zürich, CH Conrad Curdin, PD MD

Centre Hospitalier Universitaire

Erfahrungen mit Secukinumab

Vaudois (CHUV), Lausanne, CH Eich Gerhard, MD

Infektiologie und Spitalhygiene,

Session Neues zu Viruserkrankungen:

Stadtspital Triemli, Zürich, CH

Neuere virale Erkrankungen

41

Guest Speakers 2015/2016 Speaker

Eyerich Kilian, Prof.

Flaherty Keith, Prof.

Institution Topic Klinik und Poliklinik für Derma-

Psoriasis und atopische Dermatitis –

tologie, TUM, München, DE

alles das Gleiche?

Harvard University, Boston, USA

Dermatoonkologie: The molecular basis for therapeutic advances, resistance and next opportunities in melanoma therapy

Grob Daniel, MD

Universitäre Klinik für Akut-

Geriatrische Dermatologie: Hautprobleme und

geriatrie SWZ, Stadtspital Waid,

Geriatrie

Zürich, CH Harr Thomas, MD

HUG, Leitung Service

Session Allergien & Intoleranzreaktionen:

d’Allergologie, Genf, CH

Angioödeme. Medikamentös ausgelöste Angioödeme

Häusermann Peter, PD

Dermatology Departement,

Rosazea

UniversitätsSpital Basel, CH Hess-Schmid Monika, MD

Itin Peter, Prof.

Izakovic Jan, MD

Private Dermatologische Praxis,

Dermatochirurgie LIVE

Zürich, CH

Dermatology Departement,

Häufigste Hauterkrankungen im Kindesalter

UniversitätsSpital Basel, CH

Private Dermatologische, Basel,

Kindliche Gesichtsdermatosen

CH Kägi Martin, MD

Köhli Alice, MD

Krasovec Marguerite, MD

Lauener Roger, Prof.

Private Dermatologische Praxis,

Fillertherapie in der Praxis

Zürich, CH

Departement of Allergology,

Anaphylaxis im Kindesalter

Kinderspital Zürich, CH

Private Dermatologische Praxis,

Session Entzündliche Dermatosen:

Schlieren, CH

Kutane Nebenwirkungen von Biologics

Ostschweizer Kinderspital, St.

Allergieprävention bei Kindern 2016: Alles anders?!

Gallen, CH Lautenschlager Stephan, Prof.

Marazza Gionata, MD

Marghoob Ashfaq A., Prof.

Möhrenschlager Matthias, PD Dr med.

Dermatologisches Ambulato-

Session Neues zu Viruserkrankungen: Virale

rium des Stadtspitals Triemli,

Exantheme: Klinische Unterscheidungsmerkmale

Zürich, CH

Private Dermatologische Praxis,

Session Dermatochirurgie LIVE: Onkologische

Bellinzona, CH

Dermatologie und Narbenbehandlung

Memorial Sloan-Kettering Skin

Mitorganisation des Dermatoskopiekurses 2015

Cancer Center, Long Island, NY

Chefarzt Dermatologie,

Licht- und Klimatherapie des Ekzems

Hochgebirgsklinik Davos, CH Mrowietz Ulrich, Prof.

Heas Psoriasis-Center, Univ

Usere Erfolge mit Anti-IL 17 Therapien

Med Center Schleswig-Holstein, Kiel, DE Mühlstädt Michael, MD

42

HUG, Service de Dermatologie

Session Dermatochirurgie LIVE: Chirurgie

et Vénéréologie, Genf, CH

Guest Speakers 2015/2016 Speaker

Institution Topic

Müller Simon, MD

Oberarzt Dermatologie,

Wer hat Angst vor topischen Kortikosteroiden?

Universitätsspital Basel, CH

Haut und Allergie Zentrum

Geriatrische Dermatologie: Co-Chair Session

Brunnenhof Uster, CH

Klinik und Poliklinik für Derma-

Die Dermatologische Klinik am USZ vom Ausland

tologie und Allergologie,

aus gesehen

Plaza Tobias, MD

Plewig Gerd, Prof.

Klinikum der Universität München, DE Renner Ellen, Prof.

Höhengebirgsklinik Davos,

Hautsymptome als Hinweis auf Immundefizienz bei

CH / Technische Universität

Kindern

München, DE Röcken Martin, Prof.

Rümmelein Bettina, MD

Universitäts-Hautklinik

Immunologie und Dermatologie – Wegweiser

Tübingen, DE

fachübergreifender Therapieentwicklungen

Private Dermatologische Praxis,

Faltentherapie – neue Methode zur Faltentherapie

Kilchberg, CH Schachner Lawrence, Prof.

Scharffetter-Kochanek Karin, Prof.

Scheidegger Paul, MD

Pediatric Dermatology, University

Localized Scleroderma and ist managment in

of Miami Hospital, USA

children / Cases that tought me a lesson

Klinikum für Dermatologie und

Geriatrische Dermatologie: Hautalterung, geriatrische

Allergologie, Universitäts-

Dermatologie, Verbindung zu Wundheilung und

klinikum Ulm, DE

Tumoren “Entzündliche Wunden”

Private Dermatologische Praxis,

Allergologie in der Dermatologischen Praxis

Brugg, CH Signer-Brandau Doris,

Privatpraxis, Zürich, CH

Psychotherapeuting ASP Schlüer Anna-Barbara, MD

Schwieger Agnes, MD

Umgang mit schwierigen Patienten

Kinderspital Zürich, Klinische

Praktische Anwendung von Salben und Verbänden

Pflegewissenschaft, CH

bei atopischer Dermatitis

Dermatalogy Departement,

Blasenbildende Erkrankungen im Kindesalter

Kinderspital Zürich, CH Simon Dagmar, Prof.

Department of Dermatology,

Biologika – bald auch bei atopischem Ekzem?

Inselspital Bern, CH Thaçi Diamant, Prof.

Leiter Exzellenzzentrum

Hands-on Erfahrung mit Apremilast

Entzündungsmedizin, Stiftungsuniv. Lübeck, DE Torrelo Antonio, MD

Department of Dermatology, Hospital Nino Jesus, ES

Volz Andreas, MD

Oberarzt Dermatologie, Universitätsspital Basel, CH

Werfel Thomas, Prof.

Pediatric cutaneous mastocytosis

Dermatochirurgie LIVE

Stv. Klinikdirektor, Klinik für

Nahrungsmittel bei atopischer Dermatitis: Auslöser

Dermatologie, Allergologie und

oder Prävention?

Venerologie, MHH, Hannover, DE Yawalkar Nihil, Prof.

Department of Dermatology,

Neue Therapien in der Pipeline

Inselspital Bern, CH

43

Zürcher Dermatologische Fortbildungstage (June 2015 and 2016, Convention Center Zurich) www.skincancer.ch

The Zürcher Dermatologische Fortbildungstage (ZDFT) was launched in 2011 and immediately proved to be very successful as reflected by the feedback and number of participants – mainly practicing dermatologists. The fourday intensive continuing medical education event offers a mixture of plenary lectures, hands-on workshops at the Department of Dermatology, and a half-day What’s new session.

The latter provides the participants with an overview of the most important developments in the preceding year.

In 2016, about 240 Swiss dermatologists participated, which confirms the establishment of this event as one of most important congresses on dermatology in the Germanspeaking region of Switzerland.

Medical Education 2015 Subject/Title

Date Organisation

Perspectives of Immunotherapy in Melanom

Februar 5, 2015

Prof. D. Dummer

24. Bruno Bloch-Gedächtnisvorlesung

February 23, 2015

Prof. L. French, Prof. R. Dummer

Atopisches Ekzem 2015

April 16, 2015

PD Dr A. Cozzio

Interdisziplinäre Versorgung von Hautkrebspatienten

May 7, 2015

Prof. G. Hofbauer

June 24–26, 2015

Prof. L. French, Prof. R. Dummer

August 26–28, 2015

Prof. J. Hafner, Prof. R. Dummer,

Neuigkeiten über Nichtmelanom-Hautkrebs 5. Zürcher Dermatologische Fortbildungstage: Geriatrische Dermatologie 97. Jahresversammlung der SGDV Zürich 2015.

Ohne Gefässe keine Haut – ohne Haut keine Gefässe

Prof. L. French

Dermatoskopie-Kurs

September 3, 2015 (1/2 day)

Prof. R. Braun

Leichte und schwere Psoriasis – wie behandle ich

November 5, 2015

Prof. L. French

Dermatoskopie-Kurs

January 2015

PD Dr K. Kerl

EADV Resident Course in Skin Organ Transplant

March 28–29, 2015

Prof. G. Hofbauer

im Jahr 2016?

44

Medical Education 2016 Subject/Title

Date

Organisation

25. Bruno Bloch-Gedächtnisvorlesung

February 29, 2016

Prof. L. French, Prof. R. Dummer

Autoimmunerkrankungen der Haut

April 14, 2016

PD Dr A. Cozzio

Interdisziplinäre Probleme in der Dermatoonkologie:

May 19, 2016

Prof. R. Dummer

June 15–17, 2016

Prof. L. French, Prof. R. Dummer

September 16, 2016

Prof. L. French

Dermatoskopie-Kurs

September 22, 2016

Prof. R. Braun

Nationaler Psoriasis-Tag Fach-Symposium

October 27, 2016

Prof. L. French, Prof. A. Navarini

Allergologie: Von “Zuviel von” zu “Free from”

November 3, 2016

Prof. P. Schmid-Grendelmeier

Rosazea-Was hilft?

November 22, 2016

Prof. A. Navarini

Kutane Lymphome und andere seltene Hauttumoren 6. Zürcher Dermatologische Fortbildungstage: Pädiatrische Dermatologie Symposium zum Jubiläum: 100 Jahre Dermatologische Klinik

45

12 Public Relations and 100 Year Anniversary 1oo Year Anniversary of the Department of Dermatology UHZ in 2016 In 2016, we celebrated the 100th anniversary of the Department of Dermatology at UHZ. We are very proud to look back at the efforts and the accomplishments of the former directors of the department, to whom we owe the unique position of the department today.

Various activities have been dedicated to the anniversary: Scientific symposium, September 16, 2016: Three international top experts, Prof. Keith Flahery, Boston (latest review about immunotherapy in melanoma), Prof. Martin Röcken, Tübingen (latest innovations in immuno-therapy of severe inflammatory skin diseases), and Prof. Gerd Plewig, Munich (overview of our department from an international point of view), contributed to this very successful event.

100 Jahre DERMATOLOGIE

Publication: Under the leadership of Dr M. Geiges and Prof. G. Burg, and with support from C. Frey-Blanc, the comprehensive and very enriching book 100 Jahre Dermatologische Klinik Zürich was published

by Springer Verlag. It gives an overview of the development of the department – clinical aspects and research – under the former directors and highlights the current activities of our broad spectrum of dermatologic indications, with a focus on translational medicine (ISBN 978-3-662-53346-8).

Public open day, October 4, 2016: Within the department, we had more than 150 visitors – a successful and enriching experience for our staff.

VIP tour, October 25, 2016: We guided 22 guests from politics (cantonal council and health department, canton Zurich), the University of Zurich, ETH and the Board of Directors of UHZ through our department in order to provide an impression of the department’s activities and profile. Various interesting conversations with our guests completed this very fruitful evening.

46

Public relations Events for the public and patients: We regularly organize evening events on topics such as psoriasis, rosacea, acne inversa and acne, as well as information on skin cancer at the National Swiss Skin Cancer Day in May. These evenings are highly popular – we usually number about 200 participants.

Internet and Intranet: We regularly update our homepages in order to deliver the most recent and accurate content (www.dermatologie.usz.ch). We count about 5000 hits per month.

Patient information brochures: We edit our own patient information brochures about the most common skin diseases, such as skin cancer, psoriasis, acne, chronic wounds, neurodermitis and laser medicine to provide balanced and objective information to our patients. These are regularly updated, on average every two years.

Dermatologische Klinik

Das offene Bein (Ulc

us cruris)

Patienteninformation

Wir wissen weiter.

47

13 Museum of Wax Moulages

48

The Museum of Wax Moulages serves as a window to the public for current and historical research and daily practice in dermatology at UHZ and the University of Zurich.

In addition to general public visits to the museum during opening hours, there is increasing demand for museum visits as part of academic meetings, conventions and courses. Again, the traditional Lange Nacht der Museen, which takes place every year in September, is a highlight with more than 500 visitors during the evening.

ful translational research from bench to bedside. Further moulages representing research documents have been identified and documented and are displayed in the museum. The preservation and storage conditions are continuously improved and a research project was accomplished in collaboration with Bern University of the Arts (BUA) on the touch-free reproduction of wax moulages with the help of 3D scanning and 3D printing in order to improve conservation of the fragile wax objects.

Dr M. Geiges as curator and S. Carraro as restorer set their priorities on three main interests: teaching, history of dermatology and medicine, and research on the wax moulage itself. For teaching, the basic course in dermatology as part of the medical studies is given in the museum and the teaching collection serves the students as an ideal preparation for their exams, both with a very positive feedback. More historical research has been done with the focus on the 100th anniversary of the Department of Dermatology and 100 years of success-

For information about the opening hours of the museum, please consult: www.moulagen.ch

14 Honoraries and Prizes

Promotions

Honoraries, Prizes and Grants

2016: Prof. Reinhard Dummer, MD, was promoted to the status of Extraordinary Professor by the University of Zurich in September 2016.

2016: The Mycology Laboratory Mycology (directed by Dr Philipp Bosshard obtained the status of reference by e.V. Instand (German Company for quality assurance).

2015: Prof. Alexander Navarini, MD, PhD, was attributed the Bruno Bloch-Promedica Foundation Endowed Professorship for Experimental Immuno-dermatology in August 2015.

Dr Marie-Charlotte Brüggen received the scientific prize of the ÖGDV (Österreichische Gesellschaft für Dermatologie und Veneroloige) in 2016 and the Colle giality Award of the ESDR (European Society of Dermatological Research) in 2016.

Venia Legendi 2016: PD Dr Lisa Weibel, MD: title inauguration lecture “Habilitation: Innovative Aspekte der lokalisierten Sklerodermie (Morphea) im Kindesalter”

2015: PD Dr Dr Emmanuella Guenova, MD, PhD; title inauguration lecture “Dermatology and Allergology”

PD Dr univ. Katrin Kerl, MD, title inauguration lecture “Dermatopathology – Reading the Skin”

PD Dr Severin Läuchli, MD; title inauguration lecture “Mohs Chirurgie – Hautkrebs nachhaltig und ästhetisch behandeln”

Dr Martin Glatz was awarded a research prize in 2015 by the Arbeitsgemeinschaft Dermatologische For schung ADF and a research fellowship from the Ulrich Müller-Gierok Foundation in 2015. In addition, he received in January 2016 a scholarship of € 50’000 from the German Research Foundation for Derma tology ADF (Arbeitsgemeinschaft Dermatologische Forschung).

Prof. Mitchel Levesque received in 2015 a grant of CHF 100’000 from the University of Zurich for the Seed Project (Personalized Medicine) and in 2016 a grant of CHF 188,000 from the commission “Innvoa- tion”, Directorate for Research and Teaching.

Attending Physicians with extended responsibility PD Dr Katrin Kerl and PD Dr Severin Läuchli were promoted to the status of Senior Physicians with extended responsibilities in 2015, followed by the PD Dr Mirjana Maiwald in 2016.

Attending Physicians Dr Marjam Barysch and PD Dr Emmuanuella Guenova were promoted to the status of Senior Physicians in 2015, whereas Dres Martin Glatz, Joanna Mangana, Carla Murer (Winterthur), Mirjam Nägeli and Lea Wiederkehr achieved this promotion in 2016.

Dr Silvia Haueis received the poster prize, category Clinical Dermatology Oncology for her poster at the ADO Congress 2016.

Dr Carla Murer received the Bruno Bloch travel fellow- ship 2015 (Laser Skin Clinic, Dr P. André, Paris) and Dres Joanna Mangana (Peter MacCallum Cancer Center, Prof. Grant McArthur, Melbourne) and Lea Wiederkehr (E. Williams Medical Sciences Complex, Port of Spain, Trinidad) in 2016.

Prof. Alexander Navarini, together with ETH Zurich, has received the FreeNovation Grant of CHF 180’000 for 4-dimensional acne facial analysis on smart- phones.

PD Dr Lisa Weibel and Dr. Ornella Masnari (Children’s Hospital Zurich) received the SGDV Galderma 2016 prize, CHF 5’000, for the project www.hautstigma.ch.

49

In cooperation with several other departments of the University Hospital Zurich (UHZ) and Zurich Children’s Hospital, the project “Targeted and interdisciplinary treatment of severe immune-mediated diseases” was funded by the Canton of Zurich. The lead is Prof. Onur Boyman (Department of Immunology UHZ). From the Department of Dermatology Prof. Alexander Navarini, PD Dr Wolfgang Hötzenecker and Prof. Lars French are involved.

2015: Prof. Ralph Braun & the team of quality management (Dr Karin Kaufmann-Schad & Heiko Müller) received the Quality Award 2015 of the University Hospital Zurich; in addition, Prof. Braun was nominated as Expert by OnkoZert for the certification of skin tumor centers.

PD Dr Emmanuella Guenova was rewarded the fellowship-prize 2015 of the Deutschen Gesellschaft für Allergologie und Klinische Immunologie (DGAKI) and received the prize best speech and poster in the field of cutaneous autoimmune illnesses and psoriasis at the Annual Meeting of the European Association for Clinical Immunology (EAACI) 2016 in Barcelona. Addi- tionally, in 2015 she received the 20th European Research Award of the Foundation La Roche-Posay for lymphoma research.

PD Dr Simone Goldinger won the SAKK / Dr Paul Janssen Fellowship 2015 worth CHF 30’000.

Named Lectures Prof. Lars French: Memorial Lecture of the Alfred Marchionini-Stiftung, 31.1.2015, University Hamburg-Eppendorf.

50

Further Promotions Prof. Reinhard Dummer: elected as Member of the European Academy of Sciences (EUAS) in 2015.

Prof. Lars French: International Director in the Board of the Directors of the ILDS (International League of Dermatological Societies) for 2015–2023.

Prof. Lars French: elected President of the EDF (European Dermatology Forum), 2015 and 2016.

Prof. Lars French: elected Honorary Member of the Finish Society for Dermatology in 2015.

Prof. Jürg Hafner: elected Honorary Member of the French Society for Dermatology in October 2016.

Prof. Peter Schmid-Grendelmeier: elected Board Member of the SGAI (Swiss Society for Allergology and Immunology) in 2016.

Prof. Peter Schmid-Grendelmeier: elected Officer of the European Academy of Allergy and Clinical Immunology EAACI as Vice President “Education and Specialty” (2016).

15 Partners, Sponsors, Collaboration with Industry and Fundraising Our continuing efforts in medical education, public relations, marketing, and networking with private practitioners are possible only thanks to external funding. We collaborate with industry for our post-graduate education, giving private practitioners and industry a platform for communication and exchange. Furthermore, opportunities are provided by our charitable foundations, the Bruno Bloch Foundation and the Verein für Hautkrebsforschung.

We would here like to acknowledge with great respect the support of our industrial partners. Their collaboration supports the quality and nature of our post-graduate teaching offer. The Department of Dermatology UHZ is grateful to the following sponsors and donors for their generous support.

With special acknowledgement to our partners

Schwerpunkt “Hautkrebs” Amgen Switzerland AG L’Oréal/Cosmetique Active, Schweiz AG La Roche-Posay, Laboratoires Galderma Schweiz AG MSD AG Pierre Fabre Suisse SA Roche Pharma (Schweiz) AG

Schwerpunkt “Entzündliche Hautkrankheiten”

Further Corporate Supporters Actelion (Schweiz) AG ALK Abello Allergopharma AG Allergomed AG Allmiral AG Arthrex Suisse SA AstraZeneca AG Bayer (Schweiz) AG Biotest AG Bristol-Myers Squibb AG Coloplast AG CSL Behring (Schweiz) AG Dermapharm AG Drossa Pharm AG Gebro Pharma AG Geistlich Pharma AG Glaxo Smith Kline AG JCE Hottinger AG lBSA Institut Biochimique SA iQone Healthcare Europe GmbH LEO Pharma Sarath Ltd. MEDA Pharma GmbH Merck (Schweiz) AG Mundipharma Medical Company SA Nestlé Nutritionals Novartis (Schweiz) AG Permamed AG Roche Pharma (Schweiz) AG Sandoz Pharmaceuticals AG Servier (Suisse) SA Shire Switzerland GmbH Waldmann Lichttechnik

AbbVie AG Celgene GmbH Eil Lilly Suisse SA Janssen-Cilag AG Merck Sharp & Dohme AG Pfizer PFT AG Sanofi Genzyme

51

16 Publications 2015 and 2016 Publications 2015 Original Papers Amann VC, Dreier J, Ignatova D, Kamarashev J, Kerl K, Kempf W, Pascolo S, Dummer R, Cozzio A, Guenova E. Disseminated Primary Cutaneous CD8+ Small/Medium-sized Pleomorphic T-cell Lymphoma Responding to Hydroxychloroquine: Acta Derm Venereol 2015;95:602–603 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus:Inflammatory Bowel Disease and Malignancies. Journal of Crohn’s and Colitis, 2015, 945–965 doi:10.1093/ecco-jcc/jjv141 Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd-6th 2014: J Transl Med 2015;13:374 Ballmer-Weber BK, Fernandez-Rivas M, Beyer K, Defernez M, Sperrin M, Mackie AR, Salt LJ, Hourihane JOB, Asero R, Belohlavkova S, Kowalski M, de Blay F, Papadopoulos NG, Clausen M, Knulst AC, Roberts G, Popov T, Sprikkelman AB, Dubakiene R, Vieths S, van Ree R, Crevel R, Mills C. How much is too much? Threshold dose distributions for five food allergens. J Allergy Clin Immunol 2015;135:964-71 Ballmer-Weber BK, Lidholm J, Fernández-Rivas M, Seneviratne S, Hanschmann KM, Vogel L, Bures P, Fritsche P, Summers C, Knulst AC, Le TM, Reig I, Papadopoulos NG, Sinaniotis A, Belohlavkova S, Popov T, Kralimarkova T, de Blay F, Purohit A, Clausen M, Kowalski ML, Asero R, Dubakiene R, Barreales L, Clare Mills EN, van Ree R, Vieths S. IgE recognition patterns in peanut allergy are age dependent: perspectives of the EuroPrevall study. Allergy 2015;80:391-407 Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst D, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015;16:729-36 Bentele-Jaberg N, Guenova E, Mehra T, Nägeli M, Chang YT, Cozzio A, French LE, Hoetzenecker W. The Phytotherapeutic Fenugreek as Trigger of Toxic Epidermal Necrolysis. Dermatol 2015;231:99-102 Berki D, Liu L, Choon SE, Burden A, Griffiths C, Navarini A, Tan E, Irvine A, Ranki A, Ogo T, Petrof G, Mahil S, Duckworth M, Allen M, Vito P, Trembath R, McGrath J, Smith C, Capon F, Barker J. Activating CARD14 Mutations are associated with generalized Pustular Psoriasis but Rarely account for Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol 2015;135:2964-2970

52

Blanc F, Bernard H, Ah-Leung S, Przybylski-Nicaise L, Skov PS, Purohit A, de Blay F, Ballmer-Weber B, Fritsche P, Rivas MF, Reig I, Sinaniotis A, Vassilopoulou E, Hoffmann-Sommergruber K, Vieths S, Rigby N, Mills C, Adel-Patient K. Further studies on the biological activity of hazelnut allergens. Clin Transl Allergy 2015;5:26 Boehncke WH, Anliker MD, Conrad C, Dudler J, Hasler F, Häusermann P, Kyburz D, Laffitte E, Michel BA, Möller B, Navarini A, Villiger P, Yawalkar N, Gabay C. The Dermatologist’s Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. Dermatol 2015;230:75-81 Brüggen MC, Petzelbauer P, Greinix H, Contassot E, Jankovic D, French LE, Socié G, Rabitsch W, Kuzmina Z, Kahls P, Knobler R, Stingl G, Stary G. Epidermal Elafin Is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. J Invest Dermatol 2015;135:999-1006 Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, Belloni B, Raijmakers M, Goldinger S, Santoro R, Hemmi S, Sommer L, Dummer R, Levesque MP. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biol 2015;16:42 Curioni-Fontecedro A, Pitocco R, Schoenewolf NL, Holzmann D, Soldini D, Dummer R, Calvieri S, Moch H, Mihic-Probst D, Fitsche A. Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/ CT10 Expression in Mucosal Melanoma. BioMed Research International 2015;5 Datema MR, Zuidmeer-Jongejan L, Asero R, Barreales L, Belohlavkova S, de Blay F, Bures P, Clausen M, Dubakiene R, Gislason D, Jedrzejczak-Czechowicz M, Kowalski ML, Knulst AC, Kralimarkova T, Le TM, Lovegrove A, Marsh J, Papadopoulos NG, Popov T, Del Prado N, Purohit A, Reese G, Reig I, Seneviratne SL, Sinaniotis A, Versteeg SA, Vieths S, Zwinderman AH, Mills C, Lidholm J, Hoffmann-Sommergruber K, Fernández-Rivas M, Ballmer-Weber B, van Ree R. Hazelnut allergy across Europe dissected molecularly: A EuroPrevall outpatient clinic survey. J Allergy Clin Immunol 2015;136:382-91 Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, on behalf of the ESMO Guidelines Committee, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:126-132 Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, De Pril Veerle, Gurunath RK, De Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:e262.

Farnetani F, Scope A, Braun R, Gonzalez S, Guitera P, Malvehy J, Manfredini M, Marghoob A, Moscarella E, Oliviero M., Puig S, Rabinovitz H, Stanganelli I, Longo C, Malagoli C, Vinceti M, Pellacani G. Skin Cancer Diagnosis With Reflectance Confocal Microscopy Reproducibility of Feature Recognition and Accuracy of Diagnosis.

JAMA Dermatol 2015;15:1075-80

Feldmeyer L, Bogdan I, Moser A, Specker R, Kamarachev J, French LE, Läuchli S. Short- and long-term efficacy and mechanism of action of tumescent suction curettage for axillary hyperhidrosis. J Eur Acad Dermatol Venereol 2015;29:1933-7

Håkerud M, Selbo PK, Wäckerle-Men Y, Contassot E, Dziunycz P, Kündig TM, Høgset A, Johansen P. Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells. J Control Release 2015;198:10-17

Fernandez-Rivas M, Barreales L, Mackie AR, Fritsche P, VázquezCortés S, Jedrzejczak-Czechowicz M, Kowalski ML, Clausen M, Gislason D, Sinaniotis A, Kompoti E, Le TM, Knulst AC, Purohit A, de Blay F, Kralimarkova T, Popov T, Asero R, Belohlavkova S, Seneviratne SL, Dubakiene R, Lidholm J, Hoffmann-Sommergruber K, Burney P, Crevel R, Brill M, Fernández-Pérez C, Vieths S, Clare Mills EN, van Ree R, Ballmer-Weber BK. The EuroPrevall outpatient clinic study on food allergy: background and methodology. Allergy 2015;70:576-84

Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G, Müller-Brenne T, Bauch J, Eich HT, Grabbe S, Schadendorf D, Schuler G, Keikavoussi P, Semrau S, Fietkau R, Distel LV, Heinzerling L. Radiosensitization by BRAF inhibitor therapy – mechanism and frequency of toxicity in melanoma patients. Ann Oncol 2015;26:1238-1244

Gaide O, Hofbauer G, Hunger R, Mühlstädt M, Plaza T. Consensus on daylight photodynamic therapy (dl-PDT) in Switzerland. Derm Hel 2015;27:34-37 Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunzcz PJ, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF. Ingenol mebutate signals via PKC/MEK/ERK in keratinocytes and induces interleukin decoy recepotrs IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 2015;14:2132-42 Gaide O, Hofbauer G, Hunger R, Mühlstädt M, Plaza T. Consensus on daylight photodynamic therapy (dl-PDT) in Switzerland. Derm Hel 2015; 27:34-37 Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger S. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. Eur J Dermatol 2015;25:177-80 Geiges ML, Adolf Fleischmann: Arbeiten für die Chirurgie, 1917 bis 1927. In: Ruisinger MM, Schimpf S, Schnalke T: Surfaces. Adolf Fleischmann - Grenzgänger zwischen Kunst und Medizin. Kerber Art, Ingolstadt, 2015:36-65 Gerber S, Seifert B, Inci I, Serra A, Kohler M, Benden C, Hofbauer G, Schuurmans M. Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. J Eur Acad Dermatol Venereol.

2015;29:2451-7 Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SPG, Grippo JF. A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.

Pharmacol Res Perspect 2015;3:e00113 Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015;16:1389-98 Guenova E, Hoetzenecker W. Die Dermatitis herpetiformis Duhring.

Derm Hel 2015;27:40-42 Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Köberle M, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark RA, Röcken M, Biedermann T. IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA 2015;112:2163-8

Heppt MV, Reinholz M, Tietze JK, Kerl K, French LE, Berkin C, Kamarashev J. Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population.

Eur J Dermatol 2015, 25:127-32 Hussain S, Berki D, Choon SE, Burden AD, Allen M, Arostegui J, Chaves A, Duckworth M, Irvine A, Mockenhaupt M, Navarini A, Seyger M, Soler-Palacin P, Prins C, Valeyrie-Allanore L, Vicente A, Trembath R, Smith C, Barker J, Capon F. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 2015;135:1067-1070.e9 Imhof L, Meier B, Frei P, Kamarachev J, Rogler G, Kolios A, Navarini AA, Contassot E, French LE. Severe Sweet’s Syndrome with Elevated Cutaneous Interleukin-1β after Azathioprine Exposure: Case Report and Review of the Literature. Dermatology 2015;230:293-8 Iotzova-Weiss G, Dziunycz P, Freiberger S, Läuchli S, Hafner J, Vogl T, French L, Hofbauer G. S100A8/A9 Stimulates Keratinocyte Proliferation in the Development of Squamous Cell Carcinoma of the Skin via the Receptor for Advanced Glycation-End Products. PLoS ONE 10(3): e0120971 Jaimes N, Marghoob AA, Rabinovitz H, Braun RP, Cameron A, Rosendahl C, Canning G, Keir J. Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin.

J Am Acad Dermatol 2015;72:1027-35 Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms. Eur J Cancer 2015;2792-2799 Kerl K, Wolf IH, Cerroni L, Wolf P, French LF, Kerl H. Hemophagocytosis in cutaneous Autoimmune Disease. Am J Dermatopathol 2015;37:539-543 Kieliger S, Glatz M, Cozzio A, Bosshard PP. Tinea capitis and tinea faciei in the Zurich area - an 8-year survey of trends in the epidemiology and treatment patterns. J Eur Acad Dermatol Venereol 2015;29:1524-9 Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward N, Perlina A, Piris A, Zhang T, Halaban R, Herlyn M, Brown K, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. Downregulation of the ubiquitin ligase RNF125 underlies restistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Rep 2015; 1458-1473

53

Kleffel S, Posch C, Barthel SR, Müller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-Instrinsic PD-1 Receptor Functions Promote Tumor Growth.

Cell Press 2015;162:1242-1256 Kolios AG, French LE, Navarini AA. Detection of Small Changes in Psoriasis Intensity with Presice PASI. Dermatology 2015 230:314-7 Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalker N, Contassot E, Navarini AA, French LE. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 2015; 173:1216-23

Luchsinger I, Bosshard PP, Kasper RS, Reinhardt D, Lautenschlager S. Tinea genitalis: a new entity of sexually transmitted infection? Case series and review of the literature. Sex Transm Infect 2015,91:493-6 Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? PLoS One 2015;10:e0139438 Mangana J, Felderer L, Cheng P, French L, Dummer R, Schad K. Diffuse cutaneous melanosis associated with malignant melanoma.

Ann Dermatol 2015;27:780-1

Kühne Y, Reese G, Ballmer-Weber BK, Niggemann B, Haqnschmann KM, Vieths S, Holzhauser T. A novel multipeptide microarray for the specific and sensitive mapping of linear IgE-binding epitopes of food allergens. Int Arch Allergy Immunol 2015;116:213-24

Matsushita S, Krähenbühl L, Otsuka A, Mihic-Probst D, Cheng P, Dummer R, Goldinger S. Histological evaluation of a “residual” metastasis after ipilimumab therapy in a patient with advanced melanoma. J Dermatol 2015;42:1-2

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini A, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L. Corrigendum: The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2015;6:6595 (Published 03 Dec 2014, Updated 11 Mar 2015)

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600mutated melanoma in the Swiss setting. Br J Dermatol 2015; 173:1462-70

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey C.L, Lao C.D, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferruci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postwo MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:23-34 Lau E, Sedy J, Sander C, Shaw MA, Feng Y, Scortegagna M, Claps G, Robinson S, Cheng P, Srivas R, Soonthornvacharin S, Ideker T, Bosenberg M, Gonzalez R, Robinson W, Chanda SK, Ware C, Dummer R, Hoon D, Kirkwood JM, Ronai ZA. Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene 2015;34:5739-48 Lee S, Barnhill R, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep 2015;5:11200 Le TM, van Hoffen E, Kummeling I, Potts J, Ballmer-Weber BK, Bruijnzeel-Koomen CA, Lebens AF, Lidholm J, Lindner TM, Mackie A, Mills EC, van Ree R, Vieths S, Fernández-Rivas M, Burney PG, Knulst AC.Food allergy in the Netherlands: differences in clinical severity, causative foods, sensitization and DBPCFC between community and outpatients” is accepted for publication in Clinical and Translational Allergy 2015; 25: 5-8 Lichterfeld A, Hauss A, Surber C, Peters T, Blume-Peytavi U, Kottner J. Evidence-Based Skin Care: A Systematic Literature Review and the Development of a Basic Skin Care Algorithm.

J Wound Ostomy Continence Nurs 2015;42:501-24 Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol 2015;16:15-7

54

Maul JT, Carraro S, Stierlin J, Geiges M, Navarini A. Beauty and the Biologic: Artistic Documentation of Scientific Breakthrough in Psoriasis. Case Rep Dermatology 2015;7:249-252 Mehra T, Guenova E, Dechent T,Würth F, Zierhut M, Röcken M, Schaller M, Deuter C. Diagnostic relevance of direct immunofluorescence in ocular mucous membrane pemphigoid. J Dtsch Dermatol Ges 2015;13:1268-75 Mehra T, Hoetzenecker W, Moos R, Volbracht J, Guenova E, French LE, Hafner J. Inpatient treatment for severe non-surgical dermatological disorders: prevalence, care infrastructure and reimbursement in Switzerland. Dermatology 2015;231:260-8 Mehra T, Ikenberg K, Moos RM, Benz R, Nair G, Schanz U, Haralambieva E, Hoetzenecker W, Dummer R, French LE, Guenova E, Cozzio A. Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sézary Syndrome: JAMA Dermatol 2015;151:73-7 Merches K, Khairnar V, Knuschke T, Shaabani N, Honke N, Duhan V, Recher M, Navarini A, Hardt C, Häussinger D, Tümmler B, Gulbins E, Futerman A, Hoffmann D, Lang F, Lang P, Westendorf A, Lang K. Virus-Induced Type I Interferon Deteriorates Control of Systemic Pseudomonas Aeruginosa Infection. Cell Physiol Biochem 2015;36:2379-2392 Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis K, Combermale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomized, double-blind phase 2 trial. Lancet Oncol 2015:16:716-28 Mohanna M, Kamarashev J, Hofbauer G. Borrelial pseudolymphoma of the nose. BMJ Case Rep 2015. doi:10.1136/bcr-2014-205688

Mohr Peter, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatments of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologie Cooperative Oncology Group Trial. J Clin Oncol 2015;33:4077-4084 Morton C, Szeimies R, Sidoroff A, Wennberg A, Basset-Seguin N, Calzavara-Pinton P, Gilaberte Y, Hofbauer G, Hunger R, Karrer S, Lehmann P, Piaserico S, Ulrich C, Braathen L. European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol 2015;25:296-311 Otsuka A, Dreier J, Cheng PF, Nageli M, Lehmann H, Felderer L, Frew IJ, Matsushita S, Levesque MP, Dummer R. Hedgehog pathway inhibitors promote adaptive immune responses in Basal Cell Carcinoma. Clin Cancer Res 2015;21:1289-97 Raaijmakers MIG, Widmer DS, Maudrich M, Koch T, Langer A, Flace A, Schnyder C, Dummer R, Levesque MP. A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology 2015;24:377-380 Reinau D, Osterwalder U, Stockfleth E, Surber C. The meaning and implication of sun protection factor. Br J Dermatol 2015;173:1345 Reinau D, Surber C, Jick SS, Meier CR. Nonsteroidal anti-inflammatory drugs and the risk of non-melanoma skin cancer. Int J Cancer 2015;137:144-53 Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SK, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Sosman JA, Goldiner SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li YN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18 Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med. 2015;372:30-9 Rook AH, Gelfand JC, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 2015;126:1452-61 Sander P, Clark S, Petrera A, Vilaplana C, Meuli M, Selchow P, Zelmer A, Mohanan D, Andreu N, Rayner E, Dal Molin M, Bancroft GJ, Johansen P, Cardona PJ, Williams A, Böttger EC. Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis. Vaccine 2015;33:1353-1359

Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, Zarchi K, Antoniou C, Matusiak L, Lim HW, Williams M, Kwon HH, Gürer MA, Mammadova F, Kaminsky A, Prens E, van der Zee HH, Bettoli V, Zauli S, Hafner J, Läuchli S, French LE, Riad H, El-Domyati M, Abdel-Wahab H, Kirby B, Kelly G, Calderon P, Del Marmol V, Benhadou F, Revuz J, Zouboulis CC, Karagiannidis I, Sartorius K, Hagströmer L, McMeniman E, Ong N, Dolenc-Voljc M, Mokos ZB, Borradori L, Hunger RE, Sladden C, Scheinfeld N, Moftha N, Emtestam L, Lapins J, Doss N, Kurokawa I, Jemec GB. Diagnostic Delay in Hidradenitis Suppurativa is a Global Problem. Br J Dermatol 2015;173:1546-9 Scope A, Braun RP. The Recognition Process in Dermoscopy: Analytic Approach vs Heuristic Approach. JAMA Dermatol.

2015;151:704-6 Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Häusel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, Levesque MP, Dummer R, Santoro R, Cinelli P, Sommer L. Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma. PLoS Genet 2015;11:e1004877 Shain Hunter A, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D’Arrigo C, Robson A, Path FRC, Bastian BC. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015;373:1926-36 Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3K signalling is required for a TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells. Exp Dermatol 2015;24:22-8 Sollberger G, Strittmatter GE, Grossi S, Garstkiewicz M, Auf dem Keller U, French LE, Beer HD. Caspase-1 Activity Is Required for UVB-Induced Apoptosis of Human Keratinocytes.

J Invest Dermatol 2015 135:1395-404 Stimpfle DW, Serra AL, Wüthrich RP, French LE, Braun RP, Hofbauer GF. Spectophotometric intracutaneous analysis: an investigation on photodamaged skin of immunocompromised patients. J Eur Acad Dermatol Venereol 2015; 29:1141-7 Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book 2015:177-86 Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, Knuth A, Gupta A, van den Broek M. Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response.

Immunity 2015;42:1-11 Surber C, Brandt S, Cozzio A, Kottner J. Principles of skin care in the elderly. G Ital Dermatol Venereol 2015;150:699-716 Szeimies RM, Hauschild A, Ortland C, Moor AC, Stocker M, Surber C. Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions. Br J Dermatol 2015;173:1277-9 Tackenberg S, Gehrig A., Dummer R, Navarini AA. External Beam Radiotherapy of Extramammary Paget Disease. Cutis 2015;95:109-112

55

Tandjung R, Badertscher N, Kleiner N, Wensing M, Rosemann T, Braun RP, Senn O. Feasibility and diagnostic accuracy of teledermatology in Swiss primary care: process analysis of a randomized controlled trial. J Eval Clin Pract. 2015;21:326-31 Urosevic-Maiwald M, Barysch MJ, Cheng PF, Karpova MB, Steinert H, Okoniewski MJ, Dummer R. In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.

Oncolmmunology 2015;4:2, e988458 Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide Benjamin, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Genomic correlates of response to CTLA4 blockade in metastatic melanoma.Science. 2015;350:207-11 Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. Chronological Order of Appearance of Extraintestinal Manifestations to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.

Inflamm Bowel Dis 2015;21:1794-800 Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC, Mari A, Muraro A, Ollert M, Poulsen LK, Vieths S, Worm M, Hoffmann-Sommergruber K. Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens. Allergy 2015;70:1079-90 Wu X, Oliveria SA, Yagerman S, Chen L, DeFazio J, Braun R, Marghoob AA. Feasibility and Efficacy of Patient-Initiated Mobile Teledermoscopy for Short-term Monitoring of Clinically Atypical Nevi. JAMA Dermatol 2015;151:489-96 Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, Shakhova O, Dummer R, Sommer L. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun 2015;6:6051.

Reviews

DeSimone JA, Sodha P, Ignatova D, Dummer R, Cozzio A, Guenova E. Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol 2015;27:128-33 Dummer R, Goldinger SM, Paulitschke V, Levesque MP. Curing advanced melanoma by 2025. Curr Opin Oncol 2015;27:125-7 Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbé C, Hauschild A. Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? Melanoma Res 2015;25:461-9 Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The Role of Malassezia spp. in Atopic Dermatitis. J Clin Med 2015;4:1217-28 Itin P, Bosshard PP, Toutous Trellu L, Schmidt AJ, Vernazza P, Tarr P, Stoeckle M, Wymann M, Ciardo D, Walser S, Claass J, Scheidegger C, Low N, Oertle-Meyer D, Cavassini M, Schmid P, Bernasconi E, Haerry D, Boffi el Amari E, Herold M, Klimkait T, Kahlert C, Furrer H, Lautenschlager S, Calmy A, Fehr J. Syphilis Diagnostik und Behandlung. Swiss Med Forum 2015;19:459-465 Levesque MP, Dummer R, Beerenwinkel N. Perturbing resistance: a network perspective. Pigment Cell Melanoma Res 2016;29:5-7 Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol 2015;16:15-7 Navarini A, Simpson M, Borradori L, Yawalkar N, Schlapbach Chr. Homozygous Missense Mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol 2015;151:452-3 Otsuka A, Levesque MP, Dummer R, Kabashima K. Hedgehog signaling in basal cell carcinoma. J Dermatol Sci 2015;78:95-100 van Ree R, Poulsen LK, Wong GW, Ballmer-Weber BK, Gao Z, Jia X. Food allergy:definitions, prevalence, diagnosis and therapy.Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49:87-92 Widmer DS, Eichhoff OM, Dummer R, Levesque MP. Melanoma’s next top model, it is in the air. Exp Dermatol 2015;24:659-660

Zeitschrift für Onkologie 2015;5:2-5 Amann V, Dummer R. Localized Hair Repigmentation in a 91Year-Old Woman. JAMA Dermatol 2016;152:81-2

Publications 2016 Original papers

Ballmer-Weber BK. Food allergy in adolescence and adulthood.

Chem Immunol Allergy 2015; 101:51-8 Ballmer-Weber BK. Nahrungsmittelallergien bei Erwachsenen. In: Der Schweizer Allergie-Ratgeber 2015-2016 (hrsg) Mancassola L, L. Mancassola S.à.r.l., Le Mont-sur-Lausanne 2015, Kapitel II Allergene. 2. Nahrungsmittelallergien bei Erwachsenen, S. 17-23 Ballmer-Weber BK. Heuschnupfen im Frühling – Haselnussallergie im Winter: Nahrungsmittelallergien vom Schulkind bis zum Erwachsenenalter. VSAO JOURNAL ASMAC 2015;1:39-43 Cheng PF, Dummer R, Levesque MP. Data mining the cancer genome atlas in the era of precision cancer medicine. Swiss Medical Weekly 2015;145:w14183

56

Abramson MJ, Schindler C, Schikowski T, Bircher AJ, Burdet L, Gerbase MW, Imboden M, Rochat T, Schmid-Grendelmeier P, Turk AJ, Zemp E, Künzli N, Probst-Hensch N. Rhinitis in Swiss adults is associated with asthma and early life factors, but not second hand tabacco smoke or obesity. Allergol Int 2016;65:192-8 Antsiferova M, Piwko-Czuchra A, Cangkrama M, Wietecha M, Sahin D, Birkner K, Amann V, Levesque M, Hohl D, Dummer R, Werner S. Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. EMBO Molecular Medicine 2016. [Epub ahead of print] Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, Navarini AA. Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. Case Rep Dermatol 2016;8:102-106

Arora N, Schuenemann VJ, Jäger G et al. Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster. Nat Microbiol 2016;2:16245 Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the “Melanoma Bridge”. Napoli, December 1st-4th 2015. J Transl Med. 2016;14:313 Ballmer-Weber BK. Nahrungsmittelallergie: Sinn und Unsinn von diagnostischen Abklärungen. Praxis (Bern 1994) 2016;105:1019-23 Ballmer-Weber BK, Brockow K, Fiocchi A, Theler B, Vogel L, Ring J, Szépfalusi Z, Mazzina O, Schaller R, Fritsché R, Vissers YM, Nutten S. Hydrolysed egg displays stron decrease in allergenicity and is well-tolerated by egg allergic patients. Allergy 2016;71:728-32 Barysch MJ. Nicht-melanozytärer Hautkrebs. Praxis 2016;105:1071-7 Basic J, Assadian A, Strassegger J, Senekowitsch C, Wickenhauser G, Koulas S, Waldhör T, Duschek N. Degree of contralateral carotid stenosis improves preoperative risk stratification of patients with asymptomatic ipsilateral carotid stenosis. J Vasc Surg 2016;63:82-8.e2 Basmanav FB, Cau L, Tafazzoli A, Méchin MC, Wolf S, Romano MT, Valentin F, Wiegmann H, Huchenq A, Kandil R, Garcia Bartels N, Kilic A, George S, Ralser DJ, Bergner S, Ferguson DJ, Oprisoreanu AM, Wehner M, Thiele H, Altmüller J, Nürnberg P, Swan D, Houniet D, Büchner A, Weibel L, Wagner N, Grimalt R, Bygum A, Serre G, Blume-Peytavi U, Sprecher E, Schoch S, Oji V4, Hamm H, Farrant P, Simon M, Betz RC. Mutations in Three Genes Encoding Proteins Involved in Hair Shaft Formation Cause Uncombable Hair Syndrome.

Am J Hum Genet 2016;99:1292-1304 Bossart S, Schnell B, Kerl K, Urosevic-Maiwald M. Ulcers as a Sign of Skin Infection with Mycobacterium wolinskyi: Report of a Case and Review of the Literature. Case Rep Dermatol 2016;8:151-155 Bosshard PP. Diagnostik von Pilzinfektionen. Therapeutische Umschau. 2016;73:449-455.

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Brozek J, Calderon M, Canonica GW, Casale TB, Chavannes NH, Cox L, Chrystyn H, Cruz AA, Dahl R, De Carlo G, Demoly P, Devillier P, Dray G, Fletcher M, Fokkens WJ, Fonseca J, Gonzalez-Diaz SN, Grouse L, Keil T, Kuna P, Larenas-Linnemann D, Lodrup Carlsen KC, Meltzer EO, Mullol J, Muraro A, Naclerio RN, Palkonen S, Papadopoulos NG, Passalacqua G, Price D, Ryan D, Samolinski B, Scadding GK, Sheikh A, Valiulis A, Valovirta E, Walker S, Wickman M, Yorgancioglu A, Zuberbier T; MASK study group*. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol 2016;138:367-374 Brüggen MC, Bauer W, Reininger B, Clim E, Captarencu C, Steiner GE, Brunner PM, Meier B, French LE, Stingl G. In situ mapping of innate lymphoid cells in human skin: evidence for remarkable differences between normal and inflamed skin. J Invest Dermatol 2016;136:2396-2405

Carrera C, Marchetti MA, Dusza SW, Argenziano G, Braun RP, Halpern AC, Jaimes N, Kittler HJ, Malvehy J, Menzies SW, Pellacani G, Puig S, Rabinovitz HS, Scope A, Soyer HP, Stolz W, HofmannWellenhof R, Zalaudek I, Marghoob AA. Validity and Reliability of Dermoscopic Criteria Used to Differentiate Nevi From Melanoma: A Web-Based International Dermoscopy Society Study. JAMA Dermatol 2016;152:798-806 Cazzaniga S, Ballmer-Weber BK, Gräni N, Spring P, Bircher A, Anliker M, Sonntag AK, Piletta P, Huber C, Borradori L, Diepgen T, Apfelbacher C, Simon D. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol 2016;30:628-37 Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, Ronai ZA. A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. Cell Rep 2016;15:1884-92 Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget 2016 15;7:75551-75560 Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, Goldinger S.M.. Noncutaneous Melanomas: A Single-Center Analysis. Dermatology 2016;232:22-29 Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy? J Immunother 2016;39:379-382 Dirschka T, Gupta G, Micali G, Stockfleth E, Basset-Séguin N, Del Marmol V, Dummer R, Jemec GB, Malvehy J, Peris K, Puig S, Stratigos AJ, Zalaudek I, Pellacani G. Real-world approach to actinic keratosis management: Practical treatment algorithm for office-based dermatology. J Dermatolog Treat 2016;31:1-50 Dissemond J, Assenheimer B, Bültemann A, Gerber V, Gretener S, Kohler-von Siebenthal E, Koller S, Kröger K, Kurz P, Läuchli S, Münter C, Panfil EM, Probst S, Protz K, Riepe G, Strohal R, Traber J, Partsch H. Kompressionstherapie bei Patienten mit Ulcus cruris venosum. J Dtsch Dermatol Ges. 2016:1073-1089 Dissemond J, Assenheimer B, Bültemann A, Gerber V, Gretener S, Kohler-von Siebenthal E, Koller S, Kröger K, Kurz P, Läuchli S, Münter C, Panfil EM, Probst S, Protz K, Riepe G, Strohal R, Traber J, Partsch H. Compression therapy in patients with venous leg ulcers. J Dtsch Dermatol Ges. 2016;14:1072-1087 Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016;75:113-125.e5 Duschek N, Basic J, Falkensammer J, Taher F, Assadian A. B-Vitamin Serum Concentrations Predicting Long-Term Overall and Stroke-Free Survival after Carotid Endarterectomy. J Stroke Cerebrovasc Dis 2016;25:1235-43

57

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016;375:1845-1855

Garg K, Maurer M, Griss J, Brüggen MC, Wolf IH, Wagner C, Willi N, Mertz KD, Wagner SN. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol 2016;54:157-64

Eggermont A, Suciu S, Rutkowski P, Kruit W, Punt C, Dummer R, Salès F, Keiholz U, de Schaetzen G, Testori A, for the EORTC Melanoma Group. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIBeIII cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 2016;55:111-21

Glatz M, Means T, Haas J, Steere AC, Müllegger RR. Characterization of the early local immune response to Ixodes ricinus tick bites in human skin. Exp Dermatol 2017;26:263-269

El Ouaamari A, Dirice E, Gedeon N, Hu J, Zhou JY, Shirakawa J, Hou L, Goodman J, Karampelias C, Qiang G, Boucher J, Martinez R, Gritsenko MA, De Jesus DF, Kahraman S, Bhatt S, Smith RD, Beer HD, Jungtrakoon P, Gong Y, Goldfine AB, Liew CW, Doria A, Andersson O, Qian WJ, Remold-O’Donnell E, Kulkarni RN. SerpinB1 Promotes Pancreatic β Cell Proliferation. Cell Metabolisms 2016;23:194-205 Enk AH, Hadaschkin EN, Eming R, Fierlbeck G, French LE, Girolomoni G, Hertl M, Jolles S, Karpati S, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Eur Acad Dermatol Venereol 2016;10:1657-1669 Fan Y, Lee S, Wu G, Easton J, Yergeau D, Dummer R, Vogel P, Kirkwood JM, Barnhill RL, Pappo A, Bahrami A. Telomerase Expression

by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 2016;136:339-42 Farsam V, Basu A, Gatzka M, Treiber N, Schneider LA, Mulaw MA, Lucas T, Kochanek S, Dummer R, Levesque MP, Wlaschek M, Scharffetter-Kochanek K. Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. Oncotarget 2016;7:83554-83569

Glatz M. Das Hautmikrobiom und seine Bedeutung für Hauterkrankungen. Dermatologie Praxis 04/2016

Goldinger SM, Blank C. Malignes Melanom, gezielte Therapie und Immuntherapie – Der Weg zum Erfolg. Dermatologie Praxis 05/2016 Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 2016;15:4023-9 Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V, Sprikkelman AB, Roberts G, Grimshaw KEC, Sigurdardottir S, Kowalski ML, Papadopoulos NG, Quirce S, Dubakiene R, Niggemann B, Fernández-Rivas M, Ballmer-Weber B, van Ree R, Schnadt S, Mills ENC, Keil T, Beyer K. A new framework for diagnosing food allergy in population-based research. Allergy 2016; Sep 27. [Epub ahead of print] Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, Navarini AA, Mitev V, Dummer R, Kazakov DV, French LE, Hoetzenecker W, Cozzio A. Expression of CD164 on Malignant T Cells in Sézary Syndrome: Acta Derm Venereol. 2016;96:464-467 Hafner J. Calciphylaxis and Martorell Hypertensive Ischemic Leg Ulcer: Same Pattern - One Pathophysiology. Dermatology 2016;232:523-533 Hafner J, Gubler C, Kaufmann K, Nobbe S, Navarini AA, French LE. Apremilast Is Effective in Lichen Planus Mucosae-Associated Stenotic Esophagitis. Case Rep Dermatol 2016;8:224-226 Hafner J, Möhrle M, Loeser CR. Retroauricular pedicled flap for reconstruction of large helix and antihelix defects. J Dtsch Dermatol Ges 2016;14:753-5

Flux K, Kutzner H, Rütten A, Plaza JA, Gasparov S, Michal M, Guenova E, Kazakov DV. Infundibulocystic Structures and Prominent Squamous Metaplasia in Sebaceoma-A Rare Feature. A Clinicopathologic Study of 10 Cases. Am J Dermatopathol. 2016;38:678-682

Hafner J, Möhrle M, Löser CR. Retroaurikulär gestielte Lappenplastik zur Rekonstruktion großer Ohrhelix- und Anthelixdefekte. J Dtsch Dermatol Ges 2016;14:753-5

Franks PJ, Barker J, Collier M, Gethin G, Haesler E, Jawien A, Läuchli S, Mosti G, Probst G, Weller C. Management of Patients with venous leg ulcers, Challenges and current best practice. J Wound Care 2016;25 Suppl 6:S1-S67

Hasan Ali O, Diem S, Markert F, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016:5:e1231292

Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP, Dummer R, Goldinger SM. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. Br J Dermatol 2016;174:823-30

Henning B, Stieger P, Kamarachev J, Dummer R, Goldinger SM. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation.

Melanoma Res. 2016;26:304-7

Freiberger SN, Zehnder M, Gafvelin G, Grönlund H, Kündig TM, Johansen P. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human.

Allergy 2016;71:1366-70

Hjálmsdóttir Á, Wäckerle-Men Y, Duda A, Kündig TM, Johansen P. Dosing intervals in intralymphatic immunotherapy. Clin Exp Allergy 2016;46:504-7

Forsea AM, Tschandl P, Del Marmol V, Zalaudek I, Soyer HP; Eurodermoscopy Working Group., Geller AC, Argenziano G. Factors driving the use of dermoscopy in Europe: a pan-European survey.

Br J Dermatol 2016;175:1329-1337

58

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209

Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque M, Mangana J, Kerl K, Gebhardt C, Fujii H , Nakashima C , Nonomura Y , Kabashima K, Dummer R, French L. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Sci Rep 2016;6:29914 Husslik F, Nürnberg J, Seutter von Loetzen C, Mews T, Ballmer-Weber BK, Kleine-Tebbe J, Treudler R, Simon JC, Randow S, Völker E, Reuter A, Rösch P, Vieths S, Holzhauser T, Schiller D. The conformational IgE epitope profile of soya bean allergen Gly m 4. Clin Exp Allergy 2016;46:1484-1497

Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK, Beyer K, Blanca M, Brown S, Bunnag C, Hulett AC, Castells M, Chng HH, De Blay F, Ebisawa M, Fineman S, Golden DB, Haahtela T, Kaliner M, Katelaris C, Lee BW, Makowska J, Muller U, Mullol J, Oppenheimer J, Park HS, Parkerson J, Passalacqua G, Pawankar R, Renz H, Rueff F, Sanchez-Borges M, Sastre J, Scadding G, Sicherer S, Tantilipikorn P, Tracy J, van Kempen V, Bohle B, Canonica GW, Caraballo L, Gomez M, Ito K, Jensen-Jarolim E, Larche M, Melioli G, Poulsen LK, Valenta R, Zuberbier T. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 2016;12:9:33

Imhof L, Dummer R, Dreier J, Kolm I, Barysch M. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg 2016;42:853-857

Kuhn A, Zahn S, Patsinakidis N, Landmann A, Graef M, Sauerland C, Surber C, Wenzel J. Exp Dermatol. Resistance to Water and Abrasion of a Broad-Spectrum Sunscreen: A Prospective, Open-Label Study. Exp Dermatol 2016;25:151-2

Jenni D, Karpova MB, Mühleisen B, Mangana J, Dreier J, Hafner J, Dummer R. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open 2016;1:e000003. eCollection 2016.

Kulig P, Musiol S, Freiberger SN, Schreiner B, Gyülveszi G, Russo G, Pantelyushin S, Kishihara K, Alessandrini F, Kündig T, Sallusto F, Hofbauer GF, Haak S, Becher B. IL-12 protects from psoriasiform skin inflammation. Nat Commun 2016;7:13466

Klemmer A, Anzengruber F, Kazakov D, Navarini AA. White Scale Sign for Xeroderma. JAMA Dermatology 2016 Dec 14 JAMA Dermatol 2016, Dec 14. [Epub ahead of print]

Kunz M, Urosevic-Maiwald M, Goldinger SM, Frauchiger AL, Dreier J, Belloni B, Mangana J, Jenni D, Dippel M, Cozzio A, Guenova E, Kamarachev J, French LE, Dummer R. Efficacy and safety or oral alitretinoin in severe oral lichen planus – results of a prospective pilot study. J Eur Acad Dermatol Venereol 2016;30:293-8

Knoll K, Anzengruber F, Cozzio A, French LE, Murer C, Navarini AA. Mucocutaneous Ulcerations and Pancytopenia due to Methotrexate Overdose. Case Rep Dermatol 2016;8:287-293 Kolios AG, French LE, Navarini AA. Worsening of Lymphopenia during Apremilast Treatment. Case Rep Dermatol 2016;8:319-322, 2016 Kolios AG, Yawalker N, Anliker M, Boehncke WH, Borradori L, Conrad C, Gilliet M, Häusermann P, Itin P, Laffitte E, Mainetti C, French LE, Navarini AA. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology 2016;232:385-406 Konstantinova AM, Michal M, Kacerovska D, Spagnolo DV, Stewart CJ, Kutzner H, Zelger B, Plaza JA, Denisjuk N, Hejda V, Shelekhova K, Bisceglia M, Danis D, Zamecnik M, Kerl K, Guenova E, Kazakov DV. Hidradenoma Papilliferum: A Clinicopathologic Study of 264 Tumors From 261 Patients, With Emphasis on Mammary-Type Alterations. Am J Dermatopathol 2016;38:598-607 Konstantinova AM, Hayes MM, Stewart CJ, Plaza JA, Michal M, Kerl K, Kazakov DV Syringomatous Structures in Extramammary Paget Disease: A Potential Diagnostic Pitfall. Am J Dermatopathol.

2016;38:653-657 Konstantinova AM, Kacerovska D, Stewart CJ, Szepe P, Pitha J, Sulc M, Bencik V, Michal M, Shideler B, Kerl K, Kazakov DV. Syringocystadenocarcinoma Papilliferum In Situ-Like Changes in Extramammary Paget Disease: A Report of 11 Cases. Am J Dermatopathol 2016;38:882-886 Konstantinova AM, Shelekhova KV, Stewart CJ, Spagnolo DV, Kutzner H, Kacerovska D, Plaza JA, Suster S, Bouda J, Pavlovsky M, Kyrpychova L, Michal M, Guenova E, Kazakov DV. Depth and Patterns of Adnexal Involvement in Primary Extramammary (Anogenital) Paget Disease: A Study of 178 Lesions From 146 Patients.

Am J Dermatopathol 2016;38:802-808

Kyrpychova L, Kacerovska D, Vanecek T, Grossmann P, Michal M, Kerl K, Kazakov DV Cutaneous hidradenoma: a study of 21 neoplasms revealing neither correlation between the cellular composition and CRTC1-MAML2 fusions nor presence of CRTC3-MAML2 fusions. Ann Diagn Pathol 2016;23:8-13 Lacouture M, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist 2016;21:1218-1229 Läuchli S. Hautkrebs nachhaltig und ästhetisch behandeln. Medizin & Pflege ONCO MAG 2016 Läuchli S. Health Care of Chronic Wounds, Die Internationale Betrachtung chronischer Wunden. Gesellschaftspolitische Kommentare, Sonderausgabe Nr. 2/2016, Dezember 2016 Leclerc-Mercier S, Bodemer C, Furio L, Hadj-Rabia S, de Peufeilhoux L, Weibel L, Bursztejn AC, Bourrat E, Ortonne N, Molina TJ, Hovnanian A, Fraitag S. Skin Biopsy in Netherton Syndrome: A Histological Review of a Large Series and New Findings. Am J Dermatopathol 2016;38:83-91 Leinweber N, Dziunycz PJ, French LE, Wüthrich R, Serra AL, Hofbauer GF. Considerable loss of information on skin cancer occurrence and non-adherence to clinical practice guideline in renal transplant reciepents. J Eur Acad Dermatol Venereol 2016;30:1399-401 Loeser C, Hafner J. Surgical removal of atypical umbilical nevi made easy. J Dtsch Dermatol Ges 2016;14:633-5 Loeser C, Hafner J. Schonende Exzisionstechnik für atypische Naevi im Bauchnabel. J Dtsch Dermatol Ges 2016;14:633-5 Lucae S, Schmid-Grendelmeier P, Wüthrich B, Kraft D, Valenta R, Linhart B. IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment. Allergy 2016;71:115-8 59

Mainetti C, Guillod C, Leoni-Parvex S. Successful Treatment of Relapsing Bowen’s Disease with Ingenol Mebutate: The Use of Dermoscopy to Monitor the Therapeutic Response. Dermatology 2016;232.Suppl 1:9-13

Rehefeldt-Erne S, Nägeli MC, Winterton N, Felderer L, Weibel L, Hafner J, Dummer R. Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. Dermatology 2016;232:285-92

Maul J-T, Djamei V, Kolios AGA, Meier B, Czernielewski J, Jungo P, Yawalkar N, Mainetti C, Laffitte E, Spehr C, Anliker M, Streit M, Augustin M, Rustenbach S, Conrad C, Hafner J, Boehncke WH, Borradori L, Gilliet M, Itin P, French LE, Häusermann P, Navarini AA. Efficacy and survival of systemic Psoriasis treatments - an analysis of the Swiss registry SDNTT. Journal of Dermatology 2016 Dermatology. Jan 12. [Epub ahead of print]

Reinau D, Meier CR, Blumenthal R, Surber C. Skin Cancer Prevention, Tanning and Vitamin D: A Content Analysis of Print Media in Germany and Switzerland. Dermatology 2016;232:2-10

Maul JT, Kretschmer L, Anzengruber F, Pink A, Murer C, French LE, Hofbauer GF, Navarini AA. Impact of UVA on pruritus during UVA/B-phototherapy of inflammatory skin diseases - a randomized double-blind study. J Eur Acad Dermatol Venereol 2016 Oct 4.

[Epub ahead of print] Matricardi PM, Kleine-Tebbe J, Hoffmann HJ et al. EAACI Molecular Allergology User’s Guide. Pediatr Allergy and Immunol 2016;27: Suppl 23:1-25 Meier B, Maul JT & French L.E. Pyoderma gangrenosum and Sweet’s syndrome: Cutaneous manifestations of autoinflammatory disorders. Hautarzt 2016:67:934-939 Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 2016;29:404-16 Minini R, Rohrmann S, Braun R, Korol D, Dehler S. Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.

Melanoma Res 2016 Dec 6. [Epub ahead of print] Nägeli M, Läuchli S. Update venerische Proktitis 2016 bei anorektaler Symptomatik auch an venerische Krankheiten denken. Dermatologie Praxis 2016; Vol. 26, Nr. 3 Navarini AA, French LE. The skin and its blossoms - fertile soil for clinical science. Semin Immunopathol 2016; 38:1-2 Navarini AA, Satoh TK, French LE. Neutrophilic dermatoses and autoinflammatory diseases with skin involvment - innate immune disorders. Semin Immunopathol 2016;1:45-56 Niessner H, Schmitz J, Tabatabai G, Schmid A, Calaminus C, Sinnberg T, Weide B, Eigentler T, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders M, Meinhardt M, Baretton G, Dummer R, Flaherty K, Pichler B, Kulms D, Westphal D, Meier F. PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res 2016;22:5818-5828 Ramelyte E, Amann V, Dummer R. Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opinion on Pharmacotherapy 2016

60

Rinderknecht J, H.O. Ali, E. Guenova, A. Cozzio. BP180/230 – negatives bullöses Pemphigoid. Derm Hel 2016;28:22-23 Roider EM, Fisher DE. Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans. JAMA Dermatol 2016;152:751-3 Rozati S, Kempf W, Ostheeren-Michaelis S, Bode-Lesniewska B, Zimmermann DR, Dummer R, Cozzio A. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. J Clin Oncol 2016;34:e93-6 Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R. Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL. Clin Cancer Res 2016;22:2020-31 Satho TK, Mellett M, Contassot E, French LE. Are neutrophilic deramtoses autoinflammatory disorders? Br J Dermatol [Epub ahead of print], 2016 Saulite I, Roider E, Darlenksi R, Jalili A, Guenova E. Cutaneous Oncology: From Research to Diagnosis and Management. Biomed Res Int 2016;2016:7819428 Saulite I, Hoetzenecker W, Weidinger S, Cozzio A, Guenova E, Wehkamp U. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets. Biomed Res Int 2016:717530 Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O’Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert J, Hille D, Ebbinghaus S, Peter Kang S, Zhou W, Ribas A. Health-related quality of life in the randomized KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer 2016;67:46-54 Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-25 Schmid-Grendelmeier P, Ballmer-Weber B, Faeh J, Ferrari G, Grabbe J, Hausmann O, Helbling A, Hötzenecke W, Jörg L, Di Lucca J, Pletscher M, Scherer-Hofmeier K, Seebach J, Simon D, Spertini F, Spoerl D, Yawalkar N. Swiss Expert Opinion on the Management of Chronic Spontaneous Urticaria. Derm Hel 2016;28:30-35 Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infect Dis. 2016 Dec 19. pii: S1473-3099(16)30529-1. [Epub ahead of print]

Skrinjar E, Duschek N, Bayer GS, Assadian O, Koulas S, Hirsch K, Basic J, Assadian A. Randomized controlled trial comparing the combination of a polymeric membrane dressing plus negative pressure wound therapy against negative pressure wound therapy alone: The WICVAC study.Wound Repair Regen 2016;24:928-935 Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell 2016;29;270-84 Sönnichsen A, Saulite I, Mangana J, Kerl K, Mehra T, Desislava I, Chang YT, Petrausch U, Schmid-Grendelmeier P, Hoetzenecker W, Cozzio A, Guenova E. Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome. J Dermatolog Treat 2016;27:436-8.

Strittmatter GE, Sand J, Sauter M, Seyffert M, Steigerwald R, Fraefel C, Smola S, French LE, Beer HD. IFN-y primes keratinocytes for HSV-1-induced inflammasome activation. J Invest Dermatol 2016;136:610-20 Strittmatter GE, Garstkiewicz M, Sand J, Grossi S, Beer HD. Human primary keratinocytes as a tool for the analysis of caspase-1-dependent unconventional protein secretion. Methods Mol Biol 2016;1459:135-47 Strohal R, Assenheimer B, Augustin M, Hämmerle G, Läuchli S, Pundt B, Stern G, Storck M, Ulrich C. Wundbehandlung mit Enzym-Alginogelen. Der Hautarzt doi:10.1007/s00105-016-3878 Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Gutte P, Grütter M, Beer HD, Contassot E, Chan A, Rawlings D, Mair F, Becher B, Falk W, Fried M, Rogler G, Scharl M Tyrosine phosphorylation of NLRP3 on Tyr-861 is controlled by Protein tyrosine phosphatase non-receptor type 22. J Clin Invest 2016;126:1783-800 Taher F, Assadian A, Strassegger J, Duschek N, Koulas S, Senekowitsch C, Falkensammer J. Pararenal Aortic Ulcer Repair. Eur J Vasc Endovasc Surg 2016;51:504-10 Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R. An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. Br J Dermatol 2016;175:966-978 Treudler R, Franke A, Schmiedeknecht A, Ballmer-Weber BK, Worm M, Werfel T, Jappe U, Biedermann T, Schmitt J, Brehler R, Kleinheinz A, Kleine-Tebbe J, Brüning H, Ruëff F, Ring J, Saloga J, Schäkel K, Holzhauser T, Vieths S, Simon JC. Standardization of double blind placebo controlled food challenge with soy within a multicenter trial. Clin Transl Allergy 2016;6:39 Treudler R, Franke A, Schmiedeknecht A, Ballmer-Weber B, Worm M, Werfel T, Jappe U, Biedermann T, Schmitt J, Brehler R, Kleinheinz A, Kleine-Tebbe J, Brüning H, Ruëff F, Ring J, Saloga J, Schäkel K, Holzhauser T, Vieths S, Simon Jan C. BASALIT-trial: Double blind placebo controlled allergen immunotherapy with rBet v 1-FV in birch related soy allergy. Allergy. 2016 Dec 20. [Epub ahead of print]

Turner PJ, Baumert JL, Beyer K, Boyle R, Chan CH, Clark A, Crevel RW, DunnGalvin A, Fernández Rivas M, Gowland HM, Grabenhenrich L, Hardy S, Houben GF, Hourihane JO, Muraro A, Poulsen LK, Pyrz K, Remington BC, Schnadt S, van Ree R, Venter C, Worm M, Mills CE, Roberts G, Ballmer-Weber BK. Can we identify patients at risk of life-threatening allergic reactions to food. Allergy 2016: 71; 1241-55 Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. Eur J Cancer 2016:65:130-138 Uter W, Warburton K, Weisshaar E, Simon D, Ballmer-Weber B, Mahler V, Fuchs T, Geier J, Wilkinson M. Patch test results with rubber series in the European Surveillance System on Contact Allergies (ESSCA), 2013/14. Contact Dermatitis 2016; 75:345-352 van Hage M, Schmid-Grendelmeier P, Skevaki C, Plebani M, Canonica W, Kleine-Tebbe J, Nystrand M, Jafari-Mamaghani M, Jakob T., Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study. Clin Chem Lab Med 2017;55:571-577 Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, Ferrer M, Knulst A, Giménez-Arnau A. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol 2016 Nov 23.

[Epub ahead of print] Wang H, Osseiran S, Igras V, Nichols AJ, Roider EM, Pruessner J, Tsao H, Fisher DE, Evans CL. In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin Sci Rep 2016;6:37986 Weber B, Hafner J, Willenberg T, Hoerstrup SP. Bioengineered valves for the venous circulation.

Expert Rev Med Devices 2016:13:1005-1011 Weibel L, Barysch MJ, Scheer HS, Königs I, Neuhaus K, Schiestl C, Rentsch K, Müller DM, Theiler M. Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption. Pediatr Dermatol 2016;33:184-90 Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank CU, Schadendorf D, Dummer R, Ascierto PA, Hospers GA, Garbe C, Wolchok JD. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 2016;22:5487-5496 Yazdi AS, Glatz M, et al. ADF Winter School-An exciting concept of the Arbeitsgemeinschaft Dermatologische Forschung to connect young scientists and clinician scientists in Dermatology at the top of Germany. Exp Dermatol 2016, Nov 3. [Epub ahead of print] Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF. Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation. Immunology 2016, Nov 9. [Epub ahead of print] Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-25

61

Zulehner N, Nagl B, Briza P, Roulias A, Ballmer-Weber B; Zlabinger G, Ferreira F, Bohle B. Dau c 1, the Bet v 1 homolog in carrot, shows sensitizing activity, evidence at the T-cell level. Allergy 2016. May 25. [Epub ahead of print]

Reviews Amann V, Dummer R. Localized Hair Repigmentation in a 91-YearOld Woman. JAMA Dermatol 2016;152:81-2 Amann V, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger SM, Dummer R, Mangana J. Developments in targeted therapy in melanoma. Eur J Surg Oncol 10.1016. [Epub ahead of print] Bieber T, Akdis C, Lauener R, Traidl-Hoffmann C, Schmid-Grendelmeier P, Schäppi G, Allam JP, Apfelbacher C, Augustin M, Beck L, Biedermann T, Braun-Fahrländer C, Chew FT, Clavel T, Crameri R, Darsow U, Deleuran M, Dittlein D, Duchna HW, Eichenfeld L, Eyerich K, Frei R, Gelmetti C, Gieler U, Gilles S, Glatz M, Grando K, Green J, Gutermuth J, Guttman-Yassky E, Hanifin J, Hijnen D, Hoetzenecker W, Irvine A, Kalweit A, Katoh N, Knol E, Koren H, Möhrenschlager M, Münch D, Novak N, O’Mahony L, Paller AS, Rhyner C, Roduit C, Schiesser K, Schröder J, Simon D, Simon HU, Sokolowska M, Spuls P, Stalder JF, Straub D, Szalai Z, Taieb A, Takaoka R, Todd G, Todorova A, Vestergaard C, Werfel T, Wollenberg A, Ring J. Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicine. Allergy 2016;71:588-92 Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PA, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicioğlu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JO, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Kaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N’Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F,

62

Milenkovic B, Mohammad GM, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O’Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FE, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

Clin Transl Allergy 2016;6:29 Buttafuoco A, Schmid-Grendelmeier P, Glatz M. Atopische Dermatitis und Malassezia spp. Ther Umsch 2016;73:463-468 Crisan D, Scharffetter-Kochanek K, Dummer R, Treiber N, Sindrilaru A, Kastler S, Schneider LA. Beware when the hair turns dark again: clinical presentation and management of melanoma in situ in a giant congenital naevus on the scalp. J Eur Acad Dermatol Venereol 2016 Nov 23. [Epub ahead of print] Dummer R, Ramelyte E, Levesque M, Goldinger SM, Braun RP. Critical aspects to achieve a high-quality melanoma clinic. Curr Opin Oncol 2016 Dec 23. [Epub ahead of print] Dummer R, Siano M, Hunger RE, Lindenblatt N, Braun R, Michielin O, Mihic-Probst D, von Moos R, Najafi Y, Guckenberger M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016;146:w14279 Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, Germenis AE, Grumach AS, Luczay A, Varga L, Zanichelli A; HAWK.. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2016 Aug 9. [Epub ahead of print] Goldinger SM, Gobbi Bischof S, Fink-Puches R, Klemke CD, Dréno B, Bagot M, Dummer R. Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. JAMA Dermatol 2016 Mar 23. doi: 10.1001/jamadermatol.2016.0401 He Y, Maier K, Leppert J, Hausser I, Schwieger-Briel A, Weibel L, Theiler M, Kiritsi D, Busch H, Boerries M, Hannula-Jouppi K, Heikkilä H, Tasanen K, Castiglia D, Zambruno G, Has C. Monoallelic Mutations in the Translation Initiation Codon of KLHL24 Cause Skin Fragility. Am J Hum Genet 2016;99:1395-1404 Hoetzenecker W, Nägeli M, Guenova E, Mehra T, Schmid-Grendelmeier P, Cozzio A, French LE. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016;38:75-86

Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016;38:75-86 Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE. Toxic epidermal necrolysis.

F1000Res 2016;5 Krengel S, Widmer DS, Kerl K, Levesque MP, Schiestl C, Weibel L. Naevus spilus-type congenital melanocytic naevus associated with a novel NRAS codon 61 mutation. Br J Dermatol 2016;174:642-4 Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, Aalberse RC, Agache I, Asero R, Ballmer-Weber B, Barber D, Beyer K, Biedermann T, Bilò MB, Blank S, Bohle B, Bosshard PP, Breiteneder H, Brough HA, Caraballo L, Caubet JC, Crameri R, Davies JM, Douladiris N, Ebisawa M, EIgenmann PA, Fernandez-Rivas M, Ferreira F, Gadermaier G, Glatz M, Hamilton RG, Hawranek T, Hellings P, Hoffmann-Sommergruber K, Jakob T, Jappe U, Jutel M, Kamath SD, Knol EF, Korosec P, Kuehn A, Lack G, Lopata AL, Mäkelä M, Morisset M, Niederberger V, Nowak-Węgrzyn AH, Papadopoulos NG, Pastorello EA, Pauli G, Platts-Mills T, Posa D, Poulsen LK, Raulf M, Sastre J, Scala E, Schmid JM, Schmid-Grendelmeier P, van Hage M, van Ree R, Vieths S, Weber R, Wickman M, Muraro A, Ollert M. EAACI Molecular Allergology User’s Guide.

Pediatr Allergy Immunol 2016;27 Suppl 23:1-250 Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, Jutel M, Ong PY, Poulsen LK, Schmid-Grendelmeier P, Simon HU, Seys SF, Agache I. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016;137:1347-58

Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Gieler U, Kahle J, Kapp A, Nast A, Nemat K, Ott H, Przybilla B, Roecken M, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Worm M. S2k guideline on diagnosis and treatment of atopic dermatitis--short version.J Dtsch Dermatol Ges 2016;14:92-106 Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, Hoetzenecker W, Knol E, Simon HU, Wollenberg A, Bieber T, Lauener R, Schmid-Grendelmeier P, Traidl-Hoffmann C, Akdis CA. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.

J Allergy Clin Immunol 2016;138:336-49

Book chapters Braun R, Thomas L. Dermoscopie et imagérie cutanée. Dermatologie et infections sexuellement transmissibles J.-H.Saurat et al.

6ème édition Guenova E, Biedermann T. Hyper-IgE-Syndrom. In: Biedermann T., Heppt W., Renz H., Röcken M, eds. Allergologie. 2. Auflage, ed.

Springer. 2016 ISBN 978-3-642-37202-5 Geiges ML. 100 Jahre Dermatologische Klinik Zürich – 100 Jahre translationale Forschung. Springer, Berlin Heidelberg, 2017 Geiges ML. Moulagen in der Lehre – das Moulagenmuseum der Universität und des Universitätsspitals Zürich. In: Bierende E, Moos P, Seidl E (Hrsg) Krankheit als Kunst(Form) – Moulagen in der Medizin. MUT Band 12, 2016

Navarini A, French L. The skin and its blossoms – fertile soil for clinical science. Semin Immunopathol 2016;38:1-2 Navarini A, Satoh T, French L. Neutrophilic dermatoses and autoinflammatory diseases with skin involvement—innate immune disorders. Semin Immunopathol 2016;38:45-56 Ramelyte E, Schindler Sabrina A., Dummer R. The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opinion on Drug Safety 2016. [Epub ahead of print] Senti G, Kündig TM. Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and Intradermal. Immunol Allergy Clin North Am 2016;36:25-37 Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Gieler U, Kahle J, Kapp A, Nast A, Nemat K, Ott H, Przybilla B, Roecken M, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Worm M. S2k guideline on diagnosis and treatment of atopic dermatitis short version. Allergo J Int 2016;25:82-95 Werfel T, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Gieler U, Heratizadeh A, Kahle J, Kapp A, Nast A, Nemat K, Ott H, Przybilla B, Roecken M, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Worm M. Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis].

J Dtsch Dermatol Ges 2016;14:e1-75

63

HAL 31

BOL 13

University Hospital Zurich Department of Dermatology Gloriastrasse 31 8091 Zurich 2 St d.

1 Std. 2 Std.

1 Std.

c.frey-blanc@usz.ch www.dermatologie.usz.ch

HUK 2 Std.

UN 27 I GLO II

2 Std.

2 S td

.

Tramline 5 or 6, get off at “Platte”

06.17

Follow us